U.S. patent application number 17/126748 was filed with the patent office on 2021-04-22 for sustained release compositions using wax-like materials.
The applicant listed for this patent is Farnam Companies, Inc.. Invention is credited to Andrew Xian Chen, Patricia D. Kigin.
Application Number | 20210113469 17/126748 |
Document ID | / |
Family ID | 1000005290188 |
Filed Date | 2021-04-22 |
United States Patent
Application |
20210113469 |
Kind Code |
A1 |
Chen; Andrew Xian ; et
al. |
April 22, 2021 |
SUSTAINED RELEASE COMPOSITIONS USING WAX-LIKE MATERIALS
Abstract
Sustained release spherical or non-spherical pellets comprising
(a) an active ingredient (b) a wax-like agent, and (c) a
spheronizing agent are provided. Oral dosage forms comprising said
pellets and methods for preparing and using such pellets and dosage
forms are also provided.
Inventors: |
Chen; Andrew Xian; (San
Diego, CA) ; Kigin; Patricia D.; (Scottsdale,
AZ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Farnam Companies, Inc. |
Phoenix |
AZ |
US |
|
|
Family ID: |
1000005290188 |
Appl. No.: |
17/126748 |
Filed: |
December 18, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12040443 |
Feb 29, 2008 |
10888521 |
|
|
17126748 |
|
|
|
|
60904456 |
Mar 2, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/135 20130101;
A61K 31/7008 20130101; A61K 9/1652 20130101; A61K 31/522 20130101;
A01N 43/90 20130101; A61K 9/1694 20130101; A61K 9/0095 20130101;
A61K 9/1617 20130101 |
International
Class: |
A61K 9/16 20060101
A61K009/16; A61K 31/7008 20060101 A61K031/7008; A61K 31/522
20060101 A61K031/522; A61K 31/135 20060101 A61K031/135 |
Claims
1. A composition comprising: (a) an active ingredient, which is an
insect growth regulator (IGR); (b) a wax-like agent; and (c) a
spheronizing agent, wherein the composition is in the form of
pellets.
2. The composition of claim 1, wherein the IGR is a member selected
from the group consisting of methoprene, kinoprene, hydroprene,
diflubenzuron, and pyriproxifen.
3. The composition of claim 1, wherein the IGR is methoprene.
4. The composition of claim 1, wherein the IGR is
diflubenzuron.
5. The composition of claim 1, wherein the IGR is pyriproxifen.
6. The composition of claim 1, comprising: (a) from about 0.1% to
about 90% of the active ingredient; (b) from about 5% to about 40%
of the wax-like agent; and (c) from about 5% to about 40% of the
spheronizing agent.
7. The composition of claim 1, wherein the active ingredient is
present in an amount of about 0.1% to about 5%.
8. The composition of claim 1, comprising: (a) from about 0.1% to
about 5% of methoprene; (b) from about 5% to about 30% of
hydrogenated vegetable oil; (c) from about 5% to about 30% of
microcrystalline cellulose; and from about 1% to about 10%
pregelatinized starch.
9. The composition of claim 1, wherein the pellets are coated.
10. The composition of claim 1, wherein the wax-like agent is
selected from the group consisting of fatty alcohols, saturated and
unsaturated fatty acid esters, saturated and unsaturated fatty acid
glycerides, hydrogenated fats, hydrogenated vegetable oil, and
cholesterol.
11. The composition of claim 1, wherein the wax-like agent is
hydrogenated vegetable oil.
12. The composition of claim 1, wherein the spheronizing agent is
microcrystalline cellulose.
13. The composition of claim 1, further comprising an inactive
ingredient which is a member selected from the group consisting of
a binder, an antioxidant, an a colorant.
14. The composition of claim 13, wherein the one or more inactive
ingredients are present at the total concentration from about 0.01%
to about 5.0% based on the pellet weight.
15. The composition of claim 1, wherein the average diameter of the
spherical pellets are about 0.5 mm to about 1.5 mm.
16. A method for treating or preventing a pest infestation,
comprising contacting a host with a composition comprising an
effective amount of an insect growth regulator (IGR), a wax-like
agent; and a spheronizing agent, wherein the composition is in the
form of pellets.
17. The method of claim 16, wherein the IGR is a member selected
from the group consisting of methoprene, kinoprene, hydroprene,
diflubenzuron, and pyriproxifen.
18. The method of claim 16, wherein the IGR is methoprene.
19. The method of claim 16, wherein the IGR is diflubenzuron.
20. The method of claim 16, wherein the IGR is pyriproxifen.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present application is a continuation of U.S. patent
application Ser. No. 12/040,443, filed Feb. 29, 2008, which claims
priority to U.S. Provisional Patent Application No. 60/904,456,
filed Mar. 2, 2007, the disclosures of which are hereby
incorporated herein by reference in their entireties for all
purposes.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] This invention relates to sustained release compositions and
dosage forms and to methods of preparing and using such
compositions and dosage forms.
Description of the Related Art
[0003] Oral pharmaceutical dosage forms usually come in single
dosage unit forms, such as tablets or capsules. Each tablet or
capsule unit contains a fixed amount of an active ingredient.
[0004] Many active ingredients require specific release kinetics or
prolonged release. In such instances, use is made of so-called
sustained or controlled release formulations. The term "sustained
release" is often also used for formulations that show controlled
release during a prolonged period of time. Controlled release
formulations have been introduced for active ingredients that
require a specific release pattern such as a constant release
during a certain period of time, i.e., a release of an active
ingredient that minimizes peaks and drops. Various controlled
release formulations are now available that avoid temporary over-
or under-dosing of the active ingredient. Sustained release
formulations have been developed in which the release of the active
ingredient is prolonged in some way in order to maintain
therapeutic activity for a longer period of time. The terms of
"sustained release" and "controlled release" are often
interchangeable.
[0005] Sustained release formulations typically are applied to
drugs that have a short half-life or for active ingredients that
require active blood plasma levels for long periods of time. In the
former instance, multiple daily dosing can be avoided such as
b.i.d., t.i.d. or q.i.d regimens, which often lead to problems
caused by lack of patient compliance. Sustained release
formulations are more preferably applied for patients on chronic
medication where one administration suffices to maintain active
blood plasma levels for longer periods such as several days or even
weeks.
[0006] Tablet and capsule dosage forms are convenient to use but
suffer from limitations in delivering a drug that (1) requires a
very high dose for its therapeutic benefits, (2) are for patients
that do not take tablet/capsule voluntarily, or (3) are for those
with swallowing difficulties.
[0007] For instance, one tablet that contains up to 0.75-1 gram of
an active ingredient along with other inactive ingredients required
for forming the tablets often ends up with rather bulky mass with a
total weight up to 1.5-2 grams. Any further increase in active dose
(e.g., more than 1 g) would render the tablet too big to swallow.
Size of a capsule containing the same weight can be even greater
because the capsule content is usually not compressed like a
tablet.
[0008] A sustained release oral dosage form is intended to deliver
a drug in one unit for a prolonged therapeutic duration such as
1/2, 1, 2, or even 3 days. A sustained release formulation is often
not feasible as a tablet or capsule due to their unacceptably large
size. For example, for a drug that is administered 3 times a day at
500 mg each time in a non-sustained release formulation, a
once-a-day dose (i.e., 1500 mg) would result in a bulky tablet with
a total weight of greater than 2-3 grams. Such a bulky tablet would
be very difficult to swallow by a human or animal subject.
[0009] It is difficult to give tablets or capsules to animals such
as horses, cats or dogs because they do not take tablets or
capsules voluntarily, and poking down a tablet or capsule can be
very cumbersome. Similarly, some human patients do not like to or
unable to swallow tablets or capsules, especially the large
ones.
[0010] Multiparticulate formulations are of particular use in
overcoming the aforementioned shortcomings associated with tablet
or capsule formulations.
[0011] Multiparticulates are well-known dosage forms that comprise
a multiplicity of drug-containing particles whose totality
represents the intended therapeutically useful dose of a drug. A
multiparticulate dosage form can be made with a pure drug substance
or formulated with other ingredients with typical particle size of
1-2 mm or less. When taken orally, multiparticulates generally
disperse freely in the gastrointestinal tract, exit relatively
rapidly and reproducibly from the stomach, and maximize absorption.
See, for example, Multiparticulate Oral Drug Delivery (Marcel
Dekker, 1994) and Pharmaceutical Pelletization Technology (Marcel
Dekker, 1989).
[0012] A multiparticulate formulation may be represented by other
terms such as powders, granules, pellets, microspheres,
minispheres, beadlets, sachets etc. Because for each dose, multiple
units of particles are given, the term multi-unit dosage form is
used.
[0013] A multiparticuate formulation may be dosed as (1) dry powder
which is placed in mouth and swallowed with liquid, (2) dispersed
in a liquid and then swallowed, or (3) placed in a capsule. For the
1.sub.st and 2.sup.nd methods of administration, large amounts of
particles can be given. For example, 5-10 grams of spherical
pellets can be suspended in water and swallowed easily by a human
patient. For animals such as horse, a multiparticulate formulation
can be readily mixed with feed and be consumed by the animal
voluntarily. Moreover, unlike humans, animals are usually dosed
based on body weight. Animals have a tremendous variability in body
weights. For example, dogs may have body weights ranging from 2 kg
to 50 kg, requiring the dosage form be administered in very
specific quantities adjusted according to body weight of the
patient. In such instances, a multiparticulate formulation is of
particular use because its dose can be adjusted easily by weighing
or measuring by volume or counting the number of pellets to give a
wide range of dose variation, e.g., from about 10 mg (1 pellet) to
100 g (10,000 pellets).
[0014] Numerous active ingredients require sustained release
kinetics or prolonged release such as twice-a-day, preferably
once-a-day, or ever more preferable once every 2-3 days. In such
instances, use is made of so-called sustained release
multiparticulate formulations. Because of the allowance for a high
dosing volume, a sustained release multiparticulate formulation is
particularly useful for drugs that are given at a high dose, e.g.,
more than 1000 mg per dose.
[0015] Unlike the tablets where a sustained release may be obtained
by a matrix and/or coating system, known sustained release
multiparticulate formulations rely almost exclusively on a coating
system to provide a barrier to the drug release, i.e., "sustained
release coating." This is due to the greatly increased surface area
of a small pellet of 1-2 mm diameter compared to a tablet. For
example, a tablet in disc shape of 10 mm diameter and 5 mm
thickness contains the same volume as 750 spheres of 1 mm diameter.
Given the same density, the 750 spheres combined have 30 times of
the surface area of the tablet of the same weight. According to the
Noyes-Whitney equation which was developed by Noyes and Whitney in
1897:
-dM/dt=KA(Cs-C)
where -dM/dt is the drug dissolution rate of a drug from a matrix,
K is the diffusion constant, A is the surface area and (Cs-C) is
the concentration differential between the unstirred surface layer
adjacent to solid mass and bulk of the dissolution medium.
[0016] It is clear that the dissolution rate of a drug is directly
proportional to the surface of the matrix mass, i.e., a matrix
tablet or spheres. The overall drug dissolution rate of 750 spheres
of 1 mm diameter is thus 30 times faster than a tablet of the same
volume and density. In other words, a matrix tablet capable of
releasing its drug in 24 hours would release the drug in about 0.8
hour should it be converted to spheres of 1 mm diameter of the same
matrix mass. This dramatic increase in surface area and thus
dissolution rate has made sustained release spheres almost
impossible without a barrier coating, because most matrix-forming
materials and the conventional matrix manufacturing processes are
incapable of providing sufficiently prolonged drug dissolution. A
barrier coating is required for almost all known sustained release
pellets (see, U.S. Patent Application Publication No. 2006/0153908,
U.S. Pat. Nos. 5,188,841, 6,699,506, 6,897,205, and 6,436,438).
BRIEF SUMMARY OF THE INVENTION
[0017] The present invention provides pharmaceutical compositions
for sustained release of pharmaceutically active agents and methods
for preparing and using such pharmaceutical compositions. The
pharmaceutical compositions are in the form of pellets and may have
one or more of the following characteristics: (1) providing
sustained release that does not require a sustained release barrier
coating, which lowers the cost associated with the barrier coating
and decreases scale-up complexity; (2) providing the flexibility
for dosing, especially for animal patients; (3) enabling slow
release of active ingredients due to relatively large sizes of the
pellets (e.g., at least about 0.5 mm or 1 mm in diameter for
spherical pellets), which enables slow release of active
ingredients; and (4) easier to administer pharmaceutically active
agents of short half-lives and/or high doses compared to tablets or
capsules.
[0018] In one aspect, the present invention provides a composition
that comprises (a) an active ingredient, a wax-like agent, and a
spheronizing agent, (b) is in the form of pellets, and (c) provides
sustained release of the active ingredient. In certain embodiments,
the composition provides such sustained release without the need
for a sustained release barrier coating.
[0019] In certain embodiments, the pellets are uncoated. In certain
other embodiments, the pellets are coated. The coating may be a
sustained release barrier coating, a taste masking barrier, a
moisture barrier, a color barrier, or an enteric-coating.
[0020] In certain embodiments, the pellets are spherical. In other
embodiments, the pellets are non-spherical.
[0021] In certain embodiments, the composition has an in vitro
dissolution rate measured by standard USP basket method according
to Example 3 of at most about 50%, 60%, 70%, 80%, or 90% of the
active ingredient released after 2 hours.
[0022] In certain embodiments, the composition has an in vitro
dissolution rate measured by standard USP basket method according
to Example 3 of: about 10% to about 60% of the active ingredient
released after 1 hour; about 20% to about 70% of the active
ingredient released after 2 hours; about 30% to about 80% of the
active ingredient released after 4 hours; and about 40% to about
90% of the active ingredient release after 8 hours; and about 50%
to about 100% of the active ingredient release after 12 hours. In
certain embodiments, the active ingredient is glucosamine or a
pharmaceutically acceptable salt thereof.
[0023] In certain embodiments, the composition has an in vitro
dissolution rate measured by standard USP basket method according
to Example 3 of: about 0% to about 30% after 2 hours; about 5% to
about 35% after 4 hours, about 10% to about 40% after 8 hours;
about 15% to about 45% after 16 hours; about 20% to about 50% after
24 hours. In certain embodiments, the active ingredient is tramadol
or a pharmaceutically acceptable salt thereof.
[0024] In certain embodiments, upon or after oral administration,
the composition provides a 2-phase release profile, where the first
phase releases 10-60% of the active ingredient in about 1 hour and
the second phase releases the rest of the active ingredient, in a
nearly linear fashion, for at least about 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 14, 16, 18, 20, 22, or 24 hours.
[0025] In certain embodiments, the composition comprises: (a) from
about 5% to about 90% of the active ingredient; (b) from about 5%
to about 40% of the wax-like agent; and (c) from about 5% to about
40% of the spheronizing agent.
[0026] In certain embodiments, the composition may further comprise
one or more inactive ingredients. In certain embodiments, the
inactive ingredients may be binders, antioxidants or colorants. In
certain embodiments, the inactive ingredient(s) may be present at a
total concentration from about 0.01% to about 5.0% based on the
pellet weight.
[0027] In certain embodiments, the active agent may be an analgesic
or a pharmaceutically acceptable salt thereof, such as
acetaminophen, a centrally acting analgesic agent, opiate,
narcotic, nonsteroidal anti-inflammatory drugs (NSAIDS), and
salicylate. In certain embodiments, the analgesic is tramadol or a
pharmaceutically acceptable salt thereof.
[0028] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an analgesic or a pharmaceutically
acceptable salt thereof; (b) from about 5% to about 30% of
hydrogenated vegetable oil (e.g., cottonseed oil); (c) from about
5% to about 20% of microcrystalline cellulose; and (d) from about
1% to about 10% pregelatinized starch.
[0029] In certain embodiments, the active ingredient is a dietary
supplement, such as vitamins, minerals, herbs or other botanicals,
amino acids, proteins, and other nutrient substances or their
constituents. In certain embodiments, the dietary supplement is
glucosamine or a pharmaceutically acceptable salt thereof.
[0030] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of a dietary supplement or a
pharmaceutically acceptable salt thereof; (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., cottonseed oil); (c)
from about 5% to about 20% of microcrystalline cellulose; and (d)
from about 1% to about 10% pregelatinized starch.
[0031] In certain embodiments, the active ingredient is an
antiviral agent or a pharmaceutically acceptable salt thereof, such
as abacavir, acyclovir, ganciclovir, lamivudine, nelfinavir,
ritonavir, valacyclovir, foscarnet, and zidovudine, or a
derivative, prodrug or pharmaceutically acceptable salt
thereof.
[0032] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an antiviral agent or a pharmaceutically
acceptable salt thereof; (b) from about 5% to about 30% of
hydrogenated vegetable oil (e.g., cottonseed oil); (c) from about
5% to about 30% of microcrystalline cellulose; and (d) from about
1% to about 10% pregelatinized starch.
[0033] In certain embodiments, the active ingredient is an
anti-infective agent or a pharmaceutically acceptable salt thereof,
such as antibiotics (including .beta.-lactam antibiotics,
aminoglycosides, cephalosporins, macrolides, penicillins,
quinolones, sulfonamides, tetracyclines, antifungals, antimalarial
agents, antituberculotics agents, and anti-parasitics). In certain
embodiments, the anti-infective agent is azithromycin,
clarithromycin, roxithromycin, erythromycin, ciprofloxcin, a
combination of amoxicillin and clavulanate potassium, or a
derivative, prodrug, a pharmaceutically acceptable salt
thereof.
[0034] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an anti-infective agent or a
pharmaceutically acceptable salt thereof, (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., cottonseed oil), (c)
from about 5% to about 30% of microcrystalline cellulose, and (d)
from about 1% to about 10% pregelatinized starch.
[0035] In certain embodiments, the active ingredient is an antacid,
such as sodium antacid, calcium antacids, aluminum antacids,
magnesium antacids, and combinations thereof. In certain
embodiments, the antacid is aluminum hydroxide, magnesium
hydroxide, trisodium phosphate (also referred to as "sodium
phosphate tribase") or a combination of two or all of these three
compounds. In certain embodiments, the antacid is a combination of
aluminum hydroxide and magnesium hydroxide, or a combination of
trisodium phosphate and magnesium hydroxide, at a weight ratio of
about 1:3, 1:2, 1:1, 2:1, or 3:1.
[0036] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an antacid, (b) from about 1% to about
30% of hydrogenated vegetable oil (e.g., cottonseed oil), (c) from
about 5% to about 30% of microcrystalline cellulose, and (d) from
about 1% to about 10% pregelatinized starch.
[0037] In certain embodiments, the active ingredient is a high-dose
drug, such as fenbendazole, albendazole, febantel, carprofen,
ketoprofen, diclofenac, morphine, meperidine, buprenorphine,
butorphanol, metronidazole, potassium bromide, gabapentin,
zileuton, sucralfate, metformin, glipizide, nabumetone, niacin,
procainamide, tolmetin sodium, choline magnesium trisalicylate,
guaifenesin, eprosartan mesylate, etodolac, acarbose, ursodiol,
polyene phosphatidylchoine, and a pharmaceutically acceptable salt
thereof.
[0038] In certain embodiments, the composition comprises: (a) from
about 45% to about 90% of a high-dose pharmaceutically active
agent, (b) from about 5% to about 40% of hydrogenated vegetable oil
(e.g., cottonseed oil), (c) from about 5% to about 40% of
microcrystalline cellulose, and (d) from about 1% to about 10%
pregelatinized starch.
[0039] In certain embodiments, the active ingredient is an insect
growth regulator (IGR) or a pharmaceutically acceptable salt
thereof, such as methoprene, kinoprene, hydroprene, diflubenzuron,
or pyriproxifen.
[0040] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an insect growth regulator or a
pharmaceutically acceptable salt thereof; (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., cottonseed oil); (c)
from about 5% to about 30% of microcrystalline cellulose; and (d)
from about 1% to about 10% pregelatinized starch.
[0041] In certain embodiments, the pellets are coated. The coating
may or may not contribute to sustained release of the
composition.
[0042] In certain embodiments where the pellets are spherical,
their average diameter is about 0.1 mm to about 3 mm, about 0.5 mm
to about 2 mm, or 0.5 mm to about 1.5 mm.
[0043] In certain embodiments, the wax-like agent is selected from
the group consisting of fatty alcohols, saturated and unsaturated
fatty acid esters, saturated and unsaturated fatty acid glycerides,
hydrogenated fats, hydrogenated vegetable oil, and cholesterol. In
certain embodiments, the wax-like agent is hydrogenated vegetable
oil.
[0044] In certain embodiments, the wax-like sustained release agent
has a melting point at least about 40.degree. C., or 60.degree.
C.
[0045] In certain embodiments, the spheronizing agent is
microcrystalline cellulose.
[0046] In another aspect, the present invention provides a dosage
form that comprises the composition described herein.
[0047] In certain embodiments, the dosage form comprises the active
ingredient at a dose of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10 g per dose.
[0048] In certain embodiments, the dosage form further comprises
one or more inactive ingredients, such as flavorants, suspending
agents, anticaking agents, fillers, sweeteners, colorants, and
lubricants.
[0049] In certain embodiments, the dosage form further comprises
water and is in the form of an oral suspension.
[0050] In certain embodiments, the dosage form may be packaged in a
bottle, packet, pouch, sachet, or capsule.
[0051] In certain embodiments, the dosage form, upon oral
administration to a patient in need thereof, provides a plasma
concentration of the active agent at or above its minimum effective
concentration for at least about 2, 4, 6, 8, 10, 12, 14, 16, 18,
20, 24, 36, 48, 72, 96, 120, 144, or 168 hours.
[0052] In certain embodiments, the dosage form, upon oral
administration to a patient in need thereof, provides a plasma
concentration of the active agent at or above its minimum effective
concentration for a period of time that is at least about 2, 3, 4,
or 5 times of that of an immediate release formulation administered
at a standard dose.
[0053] In certain embodiments, the dosage form is suitable for
administration to a patient in need thereof at or no more than once
or twice per day, once per two, three, four, five, six, seven days,
once per one, two, three, or four weeks, or once per treatment.
[0054] In another aspect, the present application provides a method
for making spherical or non-spherical pellets comprising (i) an
active ingredient; (ii) a wax-like agent; and (iii) a spheronizing
agent, the method comprising: (a) preparing a mixture of the active
ingredient, the wax-like agent, the spheronizing agent, and a
liquid; (b) extruding said mixture to obtain an extrudate; (c)
spheronizing the extrudate to form spherical pellets or fragmenting
the extrudate to form non-spherical pellets; (d) drying the
spherical pellets; and (e) heating the dry pellets to a temperature
higher than the melting point of the wax-like agent.
[0055] For example, in certain embodiments, the present application
provides a method for making spherical pellets comprising (i) an
active ingredient; (ii) a wax-like agent; and (iii) a spheronizing
agent, the method comprising: (a) preparing a mixture of the active
ingredient, the wax-like agent, the spheronizing agent, and a
liquid; (b) extruding said mixture to obtain an extrudate; (c)
spheronizing the extrudate to form spherical pellets; (d) drying
the spherical pellets; and (e) heating the dry pellets to a
temperature higher than the melting point of the wax-like
agent.
[0056] In certain related embodiments, the present invention
provides a method for making spherical pellets comprising above
steps (a) to (d), but not above step (e).
[0057] In certain embodiments, the spherical pellets are
subsequently mixed with a flavorant or a vehicle comprising one or
more inactive ingredients, such as flavorants.
[0058] In certain embodiments, the liquid is water. In certain
other embodiments, the liquid comprises water and an organic
solvent (e.g., propylene glycol, ethanol, or isopropanol).
[0059] In certain other embodiments, the present application
provides a method for making non-spherical pellets comprising (i)
an active ingredient; (ii) a wax-like agent; and (iii) a
spheronizing agent, the method comprising: (a) preparing a mixture
of the active ingredient, the wax-like agent, the spheronizing
agent, and a liquid; (b) extruding said mixture to obtain an
extrudate; (c) fragmenting the extrudate to form non-spherical
pellets: (d) drying the non-spherical pellets; and (e) heating the
dry pellets to a temperature higher than the melting point of the
wax-like agent.
[0060] In a related aspect, the present invention provides a method
for making non-spherical pellets comprising above steps (a) to (d),
but not above step (e).
[0061] In certain embodiments, the non-spherical pellets are
subsequently mixed with a vehicle comprising one or more inactive
ingredients, such as flavorants.
[0062] In certain embodiments, the liquid is water. In certain
other embodiments, the liquid comprises water and an organic
solvent (e.g., propylene glycol, ethanol, or isopropanol).
[0063] In another aspect, the present invention also provides
spherical and non-spherical pellets produced according to the
methods described herein.
[0064] In another aspect, the present invention further provides
methods for making dosage forms that comprise the compositions
disclosed herein.
[0065] In certain embodiments, the method for making a dosage form
comprises filling the pellets disclosed herein in a suitable
container, such as capsules, bottles, and pouches.
[0066] In certain embodiments, the method for making a dosage form
comprises mixing the pellets disclosed herein with a vehicle, and
suspending the resulting mixture in water or another solution to
form oral suspension dosage form.
[0067] In certain embodiments, the method for making a dosage form
comprises mixing the pellets with human food or animal feed.
[0068] In another aspect, the present invention provides a method
of treating an animal in need thereof, comprising administering to
the animal orally a composition or a dosage form containing an
effective amount of the composition described herein.
[0069] For example, in one aspect, the present invention provides a
method for reducing pain, comprising administering orally to a
patient in need thereof a composition described herein that
comprises an effective amount of an analgesic or a pharmaceutically
acceptable salt thereof.
[0070] In another aspect, the present invention provides a method
for treating or preventing dietary deficiency, comprising
administering orally to a patient in need thereof a composition
described herein that comprises an effective amount of a dietary
supplement or a pharmaceutically acceptable salt thereof.
[0071] In another aspect, the present invention provides a method
for treating or preventing viral infection, comprising
administering orally to a patient in need thereof a composition
described herein that comprises an effective amount of an
anti-viral agent or a pharmaceutically acceptable salt thereof.
[0072] In another aspect, the present invention provides a method
for treating or preventing bacterial infection, comprising
administering orally to a patient in need thereof a composition
described herein that comprises an effective amount of an
anti-infective agent or a pharmaceutically acceptable salt
thereof.
[0073] In another aspect, the present invention provides a method
for treating or preventing gastrointestinal ulcer or disorder,
comprising administering orally to a patient in need thereof a
composition described herein that comprises an effective amount of
an antacid or a pharmaceutically acceptable salt thereof.
[0074] In certain embodiments, the method for treating or
preventing gastrointestinal ulcer or disorder comprises
administering orally to a patient in need thereof a mixture of a
composition that comprises aluminum hydroxide and magnesium
hydroxide described herein and a composition that comprises sodium
phosphate tribase described herein. In certain embodiments, the
ratio of the total weight of aluminum hydroxide and magnesium
hydroxide to sodium phosphate tribase is about 9:1.
[0075] In certain embodiments, the present invention provides a
method for treating or preventing parasite or pest infestation that
comprises administering orally to a patient in need thereof a
composition described herein that comprises an effective amount of
an insect growth regulator.
BRIEF DESCRIPTION OF THE DRAWINGS
[0076] FIG. 1. Representative dissolution profiles from spherical
and non-spherical pellets prepared according to Examples 1 and
2.
[0077] FIG. 2. Comparison of glucosamine in vitro dissolution
profiles between the pellets prepared according to Examples 1 and 2
and commercial products.
[0078] FIG. 3. Dissolution profiles from cylindrical pellets
prepared according to Example 2 measured in two months apart.
[0079] FIG. 4. In vitro dissolution of glucosamine from sustained
release spherical pellets containing glucosamine hydrochloride,
chondroitin sulfate, calcium ascorbate and manganese sulfate
prepared according to Example 5.
[0080] FIG. 5. In vitro dissolution of tramadol from spherical
pellets prepared according to Example 6.
[0081] FIG. 6. In vitro dissolution of azithromycin pellets for
oral suspension prepared according to Examples 7 and 8 and ZMAX.TM.
by Pfizer performed according to the method described in U.S. Pat.
No. 6,984,403.
[0082] FIG. 7. In vitro dissolution profiles of glucosamine from
spherical pellets by different heating conditions prepared
according to Example 17.
[0083] FIG. 8. In vitro dissolution profiles of glucosamine from
spherical pellets prepared with various oil according to Example
18.
[0084] FIG. 9. In vitro dissolution profile of tramadol from
spherical pellets prepared according to Example 19.
[0085] FIG. 10. Pharmacokinetic profiles of tramadol and its main
active metabolite, M1, in horses following oral administration of
tramadol hydrochloride sustained release spherical pellets.
[0086] FIG. 11. Pharmacokinetic profiles of tramadol and its main
active metabolite, M1, in horses following oral administration of
tramadol hydrochloride.
[0087] FIG. 12. Horse gastric pH following oral administration of
two antacid sustained release spherical pellet formulations: (1)
the formulation that contains aluminum hydroxide and magnesium
hydroxide prepared according to Example 11, and (2) the 9:1
combination of spherical pellets that contain aluminum hydroxide
and magnesium hydroxide and spherical pellets that contain sodium
phosphate tribase also prepared according to Example 11.
DETAILED DESCRIPTION OF THE INVENTION
[0088] The present invention provides pharmaceutical compositions
for sustained release of pharmaceutically active agents in the form
of pellets, which do not require the presence of a sustained
release barrier coating. In addition, the present invention
provides dosage forms that comprise such compositions. It further
provides methods for preparing and using the pharmaceutical
compositions and dosage forms.
[0089] Unless indicated otherwise, any percentage is weight by
weight (w/w) relative to the total weight of a composition or to
the total weight of a dry pellet.
[0090] As used in the present invention, the term "about" refers to
any value in the range of 90% to 110% of a specified value. For
example about 40.degree. C. refers to any temperature from
36.degree. C. to 44.degree. C.
[0091] As used in the present invention, any numerical ranges
recited herein are to be understood to include any integer within
the range and, where applicable (e.g., concentrations), fractions
thereof, such as one tenth and one hundredth of an integer (unless
otherwise indicated).
I. Compositions
[0092] In one aspect, the present invention provides a composition
that (a) comprises (i) an active ingredient, (ii) a wax-like agent,
and (Iii) a spheronizing agent, (b) is in the form of pellets, and
(c) provides sustained release of the active ingredient. In certain
embodiments, the sustained release of the active ingredient does
not require the presence of a sustained release barrier coating on
the pellets.
[0093] A. Active Ingredient
[0094] The active ingredient in the composition may be any
pharmaceutically active agent (i.e., a compound or a composition,
such as a herb extract, with beneficial pharmaceutical,
therapeutic, nutritional, or cosmetic effects).
[0095] In certain embodiments, the active agent may be an analgesic
or a pharmaceutically acceptable salt thereof, such as
acetaminophen, a centrally acting analgesic agent, opiate,
narcotic, nonsteroidal anti-inflammatory drugs (NSAIDS), and
salicylate. In certain embodiments, the active agent is a
combination of two or more analgesics or their pharmaceutically
acceptable salts thereof. In certain embodiments, the analgesic is
tramadol or a pharmaceutically acceptable salt thereof (e.g.,
tramadol HCl).
[0096] In certain embodiments, the active ingredient is a dietary
supplement, such as vitamins, minerals, herbs or other botanicals,
amino acids, proteins, and other nutrient substances or their
constituents. In certain embodiments, the active agent is a
combination of two or more dietary supplements. In certain
embodiments, the dietary supplement is glucosamine or a
pharmaceutically acceptable salt thereof.
[0097] In certain embodiments, the active ingredient is an
antiviral agent or a pharmaceutically acceptable salt thereof, such
as abacavir, acyclovir, ganciclovir, lamivudine, nelfinavir,
ritonavir, valacyclovir, and zidovudine. In certain embodiments,
the active agent is a combination of two more antiviral agents or
their pharmaceutically acceptable salts.
[0098] In certain embodiments, the active ingredient is an
anti-infective agent or a pharmaceutically acceptable salt thereof,
such as antibiotics (including .beta.-lactam antibiotics,
aminoglycosides, cephalosporins, macrolides, ketolides,
penicillins, quinolones, sulfonamides, tetracyclines, cycloserine,
vancomycin, linezolid, oxazolidinone, pyrimethamine, atovaquone,
tigecycline, glycylcyclines, anthelmintics, antifungals,
antimalarial agents, antiprotozoal agents, leprostatics,
antituberculosis agents, and anti-parasitics. In certain
embodiments, the anti-infective agent is azithromycin,
clarithromycin, roxithromycin, erythromycin, telithromycin,
ciprofloxacin, a combination of amoxicillin and clavulanate
potassium, or a pharmaceutically acceptable salt thereof. In
certain embodiments, the active agent is a combination of two or
more anti-infective agents or their pharmaceutically acceptable
salts.
[0099] In certain embodiments, the active ingredient is an antacid,
such as sodium antacids (e.g. trisodium phosphate, also referred to
as "sodium phosphate tribase"), calcium antacids (e.g. calcium
carbonate), aluminum antacids (e.g., aluminum hydroxide), magnesium
antacids (e.g., magnesium hydroxide), and combinations thereof. In
certain embodiments, the antacid is aluminum hydroxide, magnesium
hydroxide, trisodium phosphate (also referred to as "sodium
phosphate tribase") or a combination of two or all of these three
compounds. In certain embodiments, the antacid is a combination of
aluminum hydroxide and magnesium hydroxide, or a combination of
trisodium phosphate and magnesium hydroxide at a weight ratio of
about 1:3, 1:2, 1:1, 2:1, or 3:1.
[0100] In certain embodiments, the active ingredient is an insect
growth regulator (IGR) or a pharmaceutically acceptable salt
thereof, such as methoprene, kinoprene, hydroprene, diflubenzuron,
or pyriproxifen. In certain embodiments, the active ingredient is a
combination of two or more insect growth regulators or their
pharmaceutically acceptable salts.
[0101] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an insect growth regulator or a
pharmaceutically acceptable salt thereof; (b) from about 5% to
about 30% of hydrogenated cottonseed oil; (c) from about 5% to
about 30% of microcrystalline cellulose; and (d) from about 1% to
about 10% pregelatinized starch.
[0102] In certain embodiments, the active ingredient is a high dose
pharmaceutically active agent. A pharmaceutically active agent of
"high dose" refers to a pharmaceutically active agent that is
orally administered at a daily dose of about or greater than 1
mg/kg body weight to an adult human patient or an adult non-human
subject (e.g., a dog, cat, horse, pig, etc.). In certain
embodiments, the pharmaceutically active agent of the present
invention has a daily dose about or greater than 2, 3, 4, 5, 6, 7,
8, 9, 10, 20, 30, 40, or 50 mg/kg body weight for an adult human or
an adult non-human subject. In certain embodiments, the
pharmaceutically active agent of the present invention has a daily
dose about or greater than 100, 200, 250, 300, 350, 400, 450, 500,
600, 700, 800, 900, or 1000 mg for an adult human or an adult
non-human subject. In certain embodiments, the active ingredients
are those that must be given at at least about 200 mg, 300 mg, 400
mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1 g per dose in a
twice-a-day, once-a-day or once-per-treatment regimen.
[0103] Exemplary pharmaceutically active agents of high dose
include tramadol (e.g., tramadol HCl) (100 mg/dose or more),
acyclovir (200 mg/dose), acetaminophen (300 mg/dose), metformin
(e.g., metformin HCl) (500 mg/dose), gabapentin (100-800 mg/dose),
glucosamine, glucosamine sulfate, glucosamine HCl (500 mg/dose),
etc.
[0104] Additional examples of the high-dose ingredients are niacin,
azithromycin, valacyclovir, ursodiol, polyene phospholipids,
cholestyramine, chitosan, fenbendazole, albendazole, febantel,
carprofen, ketoprofen, diclofenac, morphine, meperidine,
buprenorphine, butorphanol, metronidazole, potassium salts,
zileuton, sucralfate, glipizide, nabumetone, procanamide, tolmetin
sodium, choline magnesium trisalicylate, guaifenesin, eprosartan
mesylate, etodolac, acarbose, ursodiol, polyene
phosphatidylcholine, a pharmaceutically acceptable salt thereof,
vitamins, minerals, irons, antacids, herbal extracts, and the
like.
[0105] In certain embodiments, the active ingredient is a
combination of two or more high dose pharmaceutically active agents
or their pharmaceutically acceptable salts. The two or more high
dose pharmaceutically active agents may or may not have similar
pharmaceutical effects.
[0106] A"pharmaceutically acceptable salt" of a pharmaceutically
active agent refers to a salt (including an acid addition salt) of
the pharmaceutically active agent, within the scope of sound
medical judgment, suitable for use in contact with the tissues of
humans and lower animals without undue toxicity, irritation,
allergic response, and the like, and effective for the intended use
of the pharmaceutically active agent.
[0107] In certain embodiments, the active ingredient is
therapeutically effective for a human (e.g., an adult human
patient) or non-human subject (e.g., a dog, a cat, a horse, a pig,
etc.) at a daily dose of at least about 5 mg/kg of the body weight
of the subject, such as at least about 7.5, 10, 12, 14, 16, 18, 20,
25, 30, 35, 40, or 50 mg/kg of the body weight of the subject.
[0108] In certain embodiments, the active ingredient has a short
half-life. A pharmaceutically active agent of "short half-life"
refers to a pharmaceutically active agent that has a half-life
about or less than 10 hours. In certain embodiments, the
pharmaceutically active agent of the present invention has a
half-life of about or less than about 9, 8, 7, 6, 5, 4, 3, or 2
hours in a human (e.g., an adult human patient) or non-human
subject (e.g., a dog, cat, horse, pig, etc.). In general, a
pharmaceutically active agent of a short half-life is required to
be taken more than twice a day in its immediate release forms to
maintain the efficacious blood concentration level through the
day.
[0109] In certain embodiments, the active ingredient is of both
short half-life and high dose. Such active ingredients include, but
not limited to verapamil HCl, potassium chloride, cefdnir,
propafenone HCl, hydroxyurea, hydrocodone bitartrate, delavirdine
mesylate, nelfinavir mesylate, pentosan polysulfate sodium,
tocainide HCl, quetiapine fumarate, fexofenadine HCl, carafate,
rifampin, moxifloxacin HCl, praziquantel, ciprofloxacin, phosphate
sodium potassium, methenamine mandelate, santalol HCl, cefprozil,
cefadroxil, metformin HCl, irbesartan, nefazodone HCl,
gatifloxacin, didanosine, modafinil, efavirenz, metaxalone,
amantadine HCl, morphine sulfate, mefenamic acid, diltiazem HCl,
sevelamer HCl, albendazole, amoxicillin, clavulanate potassium,
lithium carbonate, lamivudine, sumatriptan succinate, nabumetone,
zidovudine, cimetidine, chlorpromazine HCl, valacyclovir HCl,
bupropion HCl, ranitidine, abacavir sulfate, acyclovir,
aminobenzoate potassium, pyridostigmine bromide, potassium
chloride, isosorbide mononitrate, nicin, demeclocycline HCl,
cefixime, naproxen sodium, tetratcycline HCl, cefuroxime axetil,
propoxyphene napsylate, pyrazinamide, flecaimide acetate,
simethicone, mebendazole, methdopa, chlorothiazide, indinavir,
penicillamine, meyyrosine, losartan potassium, thiobendazole,
norfloxacin, hydroxyurea, procainamide, entacapone, valsartan,
terbinafine HCl, metoprolol tartrate, ofloxacin, levofloxacin,
chlorzoxazone, tolmetin sodium, tramadol HCl, bepridil HCl,
phenytoin sodium, atorvastatin calcium, gabapentine, celecoxib,
fluconazole, doxepine HCl, trovafloxacin mesylate, azithromycin,
sertraline HCl, rifabutin, cefpodoxime proxetil, mesalamine,
etidronate disodium, nitrofurantoin, choline magnesium
trisalicylate, theophylline, nizatidine, pancreatin, quinidine
sulfate, methocarbamol, mycophenolate mefetil, gancicovir,
saquinavir mesylate, tolcapone, ticlopidine HCl, valganciclovir
HCl, capecitabine, orlistat, colsevelam HCl, irbesartan, succimer,
meperidine HCl, hydroxychloroquine sulfate, guaifenesine,
eprosartan mesylate, amiodarone HCl, felbamate, pseudoephedrine
sulfate, carisoprodol, venlafaxine, propanolol HC, etodolac,
acebutolol, chondroitin, pyruvate, water soluble vitamins,
creatine, Isoflavone, betaine HCl, psyllium, pantothenic Acid, zinc
chloride, zinc gluconate, zinc sulfate, hytoestrogen, pycnogenol,
proanthocyanidin, suntheanine, methylsulfonyl-methane, L-glutamine,
colostrums, biotin, acetyl-L-carnitine, inositol, L-tyrosine,
s-adenosyl methionine, bromelain, 2-dimethylaminoethanol, chromium
picolinate, and combinations thereof.
[0110] In certain embodiments, the active ingredient may be
insoluble, slightly soluble, sparingly soluble, soluble, freely
soluble or very soluble in water. These terms are defined in the
following table from Remington's Pharmaceutical Sciences, Mack
Publishing Co., Easton, Pa., the latest edition.
TABLE-US-00001 Parts of solvent needed Descriptive terms for 1 part
solute Very soluble <1 Freely soluble 1-10 Soluble 10-30
Sparingly soluble 30-100 Slightly soluble 100-1000 Very slightly
soluble 1000-10,000 Practically insoluble or insoluble
>10,000
[0111] In certain embodiments, the active ingredient is present in
an amount of at least about 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%,
35%, 40%, 45%, or 50%, 55%, or 60% of the total weight of the
composition. In certain embodiments, the active ingredient is
present in an amount of at most about 65%, 70%, 75%, 80%, 85%, 90%,
or 95% of the total weight of the composition. In certain
embodiments, the active ingredient is present in the range of from
about 0.1% to about 95%, such as from about 40% to about 85%, from
about 50% to about 75%, from about 55% to about 70%, or from about
60% to about 65%, or any other range between any one of the
above-noted minimum amount and any one of the above-noted maximum
amount, w/w relative to the total weight of the composition.
[0112] In certain embodiments, the composition may further comprise
a second pharmaceutically active agent. In certain embodiments, the
second pharmaceutically active agent may be of high dose and/or
short half-life. For example, in certain embodiments, the active
ingredient may comprise glucosamine hydrochloride and chondroitin
sulfate, tramadol hydrochloride and glucosamine hydrochloride, or
tramadol hydrochloride and acetaminophen.
[0113] In certain embodiments, the other pharmaceutically active
agent may have a same or similar pharmaceutical effect as the first
pharmaceutically active agent in a pharmaceutical composition. For
instance, a pharmaceutical composition of the present invention may
comprise tramadol and another analgesic agent, in certain
embodiments, the second pharmaceutically active agent may have a
pharmaceutical effect different from the first pharmaceutically
active agent. For instance, a pharmaceutical composition of the
present invention may comprise glucosamine, chondroitin, manganese
sulfate and calcium ascorbate.
[0114] In the embodiments where a pharmaceutical composition
comprises two or more pharmaceutically active agents that produce
an additive pharmaceutical effect, the amount of each agent is
generally lower than that used for each agent in monotherapy (i.e.,
when the agents are given alone). For example, in one embodiment,
the dose of each agent in the composition may be from 0.1 to 0.75
of the dose used in monotherapy, such as from 0.25 to 0.75 of the
dose used in monotherapy. In another embodiment, the dose of one
agent is one quarter of its normal dose used in monotherapy, and
the dose of the other agent is three quarters of its normal dose
used in monotherapy. In another embodiment, the dose of each agent
is approximately one half of its normal dose when used in
monotherapy.
[0115] In the embodiments where a pharmaceutical composition
comprises two or more pharmaceutically active agents that produce a
synergistic pharmaceutical effect, the combined dose of the agents
is lower than that if the two agents produce only an additive
pharmaceutical effect. For example, in one embodiment, the dose of
one agent is one quarter of its normal dose used in monotherapy,
and the dose of the other agent is also quarter of its normal dose
used in monotherapy.
[0116] In the embodiments where a pharmaceutical composition
comprises two or more agents that produce different pharmaceutical
effects, the amount of each agent should be sufficient to produce
the intended effect of the agent. In most of embodiments, the dose
of each agent is similar to that used in monotherapy. In certain
other embodiments, the dose of each agent may be higher or lower
than that used in monotherapy.
[0117] The weight ratio of the first agent to the second agent in a
pharmaceutical composition of the present invention depends on both
agents and their dosages used in monotherapy. In certain
embodiments, the weight ratio of the first agent to the second
agent in a pharmaceutical composition is from about 1:1000 to
1000:1, such as 1:100 to 100:1, 1:50 to 50:1, 1:10 to 10:1, 1:5 to
5:1, 1:2 to 2:1.1:1 to 1:10, 1:1 to 1:50, 1:1 to 1:100, 100:1 to
1:1, 50:1 to 1:1, or 10:1 to 1:1.
[0118] In certain embodiments, the pharmaceutical composition
comprises tramadol and another analgesic agent. For example, in
certain embodiments, the pharmaceutical composition comprises
tramadol and an opioid analgesic. In certain other embodiments, the
pharmaceutical composition comprises tramadol and a non-steroidal
anti-inflammatory drug (NSAID).
[0119] Exemplary opioid analgesics that may be included in
tramadol-containing pharmaceutical compositions include, but are
not limited to, alfentanil, alphaprodine, anileridine, apomorphine,
betaprodine, buprenorphine, butorphanol, carfentanil, codeine,
codeine, cyclorphan, cyclazocine, dextromethorphan,
dextropropoxyphene, diamorphine (heroin), dihydrocodeine,
diphenoxylate, ethoheptazine, etorphine, fentanyl, hydrocodone,
hydromorphone, isomethadone, levallorphan, levorphanol, loperamide,
meperidine, methadone, metopon, morphine, morphinone, nalbuphine,
normorphine, N-(2-phenylethyl)-normorphine, oxycodone, oxymorphone,
pentazocine, pethidine (meperidine), phenazocine, piminodine,
propoxyphene, racemorphan, remifentanil, and sufentanil.
[0120] Exemplary NSAIDs that may be included in tramadol-containing
pharmaceutical compositions include, but are not limited to,
aspirin, carprofen, deracoxib, etodolac, firocoxib, celecoxib,
diclofenac, diflunisal, fluriprofen, ibuprofen, indomethacin,
ketoprofen, kietorolac, mefenamic acid, meloxicam, naproxen,
phenylbutazone, piroxicam, rofecoxib, sulindac, and valdecoxib.
[0121] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and acetaminophen. In
a certain embodiment, the weight ratio of tramadol to acetaminophen
in the composition is from about 1:10 to about 1:5.
[0122] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and diclofenac. In a
certain embodiment, the weight ratio of tramadol to diclofenac is
about 1:4 to 4:1, such as 1:2 to 3:1, and 1:1 to 2.5:1.
[0123] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and aspirin. In a
certain embodiment, the weight ratio of tramadol to aspirin is
about 1:4 and 4:1, such as between 1:2 and 2:1. In certain
embodiments, the pharmaceutical compositions of the present
invention comprise both tramadol and carprofen. In a certain
embodiment, the weight ratio of tramadol to carprofen is about 3:1
to 10:1.
[0124] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and flupirtine. In a
certain embodiment, the weight ratio of tramadol to flupirtine is
about 1:1 to 1:5.
[0125] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and codeine or
oxycodone. In a certain embodiment, the weight ratio of tramadol to
codeine or oxycodone is about 1:20 to about 20:1, such as about 1:2
to about 2:1 and about 1:1 to 2:1.
[0126] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and a NSAID, wherein
the weight ratio of tramadol to the NSAID is about 1:1 to about
1:200, from about 1:2 to about 1:200, and about 1:2 to about
1:20.
[0127] In certain embodiments, the pharmaceutical compositions of
the present invention comprise both tramadol and a calcium channel
antagonist (e.g., nimodipine, nicardipine, nifedipine, diltiazem,
verapamil, gallopamil, flunarizine, and cinnarizine). In a certain
embodiment, the weight ration of tramadol to the calcium channel
antagonist is about 200:1 to about 5:1.
[0128] In certain embodiments, the tramadol-containing
pharmaceutical compositions of the present invention further
comprise ketoprofen, cyproheptadine (serotonin antagonist),
prozosin (.alpha.-1-adrenoceptor antagonist), clonidine
(.alpha.-2-adrenoceptor agonist), clomipramine (selective inhibitor
of serotonin neuronal uptake), or xylamine (selective irreversible
inhibitor of norepinephrine uptake).
[0129] In certain embodiments, the pharmaceutical compositions of
the present invention comprise glucosamine and an analgesic, such
as a NSAID. Exemplary NSAIDs include, but are not limited to,
aspirin; phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine,
dipyrone and apazone; indomethacin; sulindac; fenamates such as
mefenamic, meclofenamic, flufenamic, tolfenamic and etofenamice
acids; aryl acetic acid and propionic acid compounds such as
2-(p-isobutylphenyl)propionic acid (ibuprofen);
alphamethyl-4-(2-thienylc-arbonyl) benzene acetic acid (suprofen);
4,5-diphenyl-2-oxazole propionic acid (oxprozin);
rac-6-chloro-alphamethyl-carbazole-2-acetic acid (carprofen);
2-(3-phenyloxyphenyl)-propionic acid, particularly the calcium salt
dihydrate thereof (fenoprofen and fenoprofen calcium);
2-(6-methoxy-2-naphthyl) propionic acid (naproxen);
4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-.alpha.-methylbenzene acetic
acid (indoprofen); 2-(3-benzoylphenyl)propionic acid (ketoprofen);
and 2-(2-fluoro-4-biphenylyl) propionic acid (flurbiprofen) and
1-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid (tolmetin).
Additional exemplary NSAIDs are compounds within the class
including sodium
5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetate dihydrate
(zomepirac sodium);
4-hydroxy-2-methyl-N-(2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-di-
oxide (piroxicam); 2',4'-difluoro-4-hydroxy-3-biphen-ylcarboxylic
acid (diflunisal) or
1-isopropyl-7-methyl-4-phenyl-2(1H)-quin-ozolinone (proquazone),
and Cox-2 inhibitors such as rofecoxib and celecoxib.
[0130] In certain embodiments, the weight ratio of glucosamine to
the analgesic in the above pharmaceutical compositions is from
about 1:10 to about 100:1, such as from about 1:1 to about 20:1,
and about 1:2 to about 10:1.
[0131] In certain embodiments, the glucosamine-containing
pharmaceutical compositions of the present invention further
comprise ibuprofen, diclofenac, tramadol, or acetaminophen. In
certain embodiments, the weight ratio of glucosamine to ibuprofen,
diclofenac, tramadol, or acetaminophen is from about 1:10 to about
100:1, such as from about 1:1 to about 20:1, and about 1:2 to about
10:1.
[0132] In certain embodiments, the pharmaceutical composition of
the present invention comprises glucosamine (e.g., glucosamine
hydrochloride and glucosamine sulfate), hydrolyzed collagen, and a
bioflavanol (e.g., proanthocyanidin, leucocyanidin, pcynogenol, and
those extracted from grape seeds, pine bark or turmeric root).
[0133] B. Wax-Like Agents
[0134] The compositions of the present invention also comprise a
wax-like agent that is a pharmaceutically acceptable material
capable of forming, together with the active ingredient and
spheronizing agent, spherical or non-spherical pellets, and
providing sustained release of the active ingredient.
[0135] A "wax-like agent," as used herein, refers to a natural,
semi-synthetic or synthetic material that is plastic (i.e.,
malleable) at normal ambient temperatures (i.e., 20-25.degree. C.),
has a melting point above 40.degree. C., is very slightly soluble,
practically Insoluble, or insoluble in water (e.g., having a
water-solubility lower than about 1:5000 (w/w)), and is composed of
an ester of a fatty alcohol and saturated and unsaturated fatty
acid(s), saturated and unsaturated fatty acid glyceride (mono-, di-
or triglyceride), hydrogenated fat, hydrogenated vegetable oil,
cholesterol, hydrocarbon, hydrophobic polymer having a hydrocarbon
backbone, hydrophilic polymer having a hydrocarbon backbone, or a
combination of one or more of the above-listed compounds.
[0136] A wax-like agent, as used herein, includes commonly known
wax, such as animal and insect waxes (e.g., beeswax, Chinese wax,
shellac wax, spermaceti wax, lanolin wax), vegetable waxes (e.g.,
bayberry wax, candelilla wax, camauba wax, castor wax, esparto wax,
Japan was, jojoba oil, ouricury wax, rice bran wax), mineral waxes
(e.g., ceresin waxes, montan wax extracted from lignite and brown
coal, ozocerite, peat waxes), petroleum waxes (e.g., paraffin wax,
microcrystalline wax), and synthetic waxes (e.g., polyethylene
waxes, Fischer-Tropsch waxes, chemically modified waxes (e.g.,
esterified or saponified waxes), substituted amide waxes, and
polymerized .alpha.-olefins). In certain embodiments, the wax is an
ester of ethylene glycol and two fatty acids.
[0137] The term "pharmaceutically acceptable," as used herein,
refers to being compatible with other ingredients of the
composition and not deleterious to the recipient thereof.
[0138] In certain embodiments, the wax-like agent is thermoplastic
with a melting point above 40.degree. C. (e.g., above 45.degree.
C.), and below 120.degree. C. (e.g., below 110.degree. C.),
including any value between 40.degree. C. and 120.degree. C. in
certain embodiments, the wax-like agent has a melting point in a
range formed by any two values between 40.degree. C. and
120.degree. C., such as between 50.degree. and 100.degree. C.,
[0139] To meet the desire for sustained release, the wax-like agent
should be substantially non-degradable and insoluble in
gastrointestinal fluids under the relevant time frame (e.g., for
10-12 hours when used in composition that provides sustained
release for twice per day administration) and at least under the
initial release phase (e.g., the first hour, the first two hours,
or the first three hours).
[0140] In certain embodiments, the wax-like agent is hydrogenated
vegetable oils, such as hydrogenated cottonseed oil, partially
hydrogenated cottonseed oil, hydrogenated soybean oil, partially
hydrogenated soybean oil, and stearyl alcohol.
[0141] In certain embodiments, the wax-like agent is present in the
composition in an amount of at least about 1%, 2%, 3%, 4%, 5%, 6%,
7%, 8%, 9%, or 10% of the total weight of the composition. In
certain embodiments, the wax-like agent is present in an amount of
at most about 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the
total weight of the composition. In certain embodiments, the
wax-like agent is present in the range of from about 1% to about
40%, such as from about 1% to about 30%, from about 5% to about
40%, from about 5% to about 40%, or any other range between any one
of the above-noted minimum amount and any one of the above-noted
maximum amount, w/w relative to the total weight of the
composition.
[0142] C. Spheronizing Agent
[0143] The compositions of the present invention further comprise a
spheronizing agent that is a pharmaceutically acceptable material
capable of forming, together with the wax-like sustained release
agent and active ingredient, spherical and non-spherical
pellets.
[0144] A "spheronizing agent," as used herein, refers to an agent
that together with an active ingredient and a wax-like agent, forms
a cohesive plastic mass that may be subsequently spheronized to
produce spherical pellets or fragmented to form non-spherical
pellets.
[0145] In certain embodiments, the spheronizing agent is
microcrystalline cellulose, such as the product sold under the
tradename "AVICEL.TM.." Other exemplary spheronizing agents include
sodium carboxymethylcellulose, pregelatinized starch (e.g.,
pregelatinized corn starch). In certain embodiment, the
spheronizing agent is a combination of microcrystalline cellulose
and pregelatinized starch.
[0146] In certain embodiments, the spheronizing agent (e.g.,
microcrystalline cellulose or a combination of microcrystalline
cellulose and pregelatinized starch) is present in the composition
in an amount of at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
or 10% of the total weight of the composition. In certain
embodiments, the spheronizing agent is present in an amount of at
most about 11%, 12%, 13%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%,
45%, or 50% of the total weight of the composition. In certain
embodiments, the spheronizing agent is present in the range from
about 5% to about 40%, such as about 5% to about 20%, from about 8%
to about 15%, or from about 9% to about 12%, or any other range
between any one of the above-noted minimum amount and any one of
the above-noted maximum amount, w/w relative to the total weight of
the composition.
[0147] D. Sustained Release
[0148] The composition of the present invention provides sustained
release of the active ingredient.
[0149] The term "sustained release," as used in describing the
present invention, refers to the release of the active ingredient
more slowly than that from an immediate release dosage form. The
term may be used interchangeably with "slow-release," "controlled
release," or "extended release." The sustained release property of
a composition is typically measured by an in vitro dissolution
method and confirmed by an in vivo blood concentration-time profile
(i.e., a pharmacokinetic profile).
[0150] The term "Immediate release dosage forms" refers to release
forms wherein at least 75% of the active ingredient is released or
dissolved within about one-half hour after administration. Such
immediate release dosage forms include tablets, capsules,
multiparticulates, powders for oral suspension and sachets of an
active ingredient. Examples of immediate release dosage forms
include, but are not limited to, commercially available various
glucosamine tablet and capsule products as described herein in
Example 3.
[0151] In certain embodiments, the pharmaceutical compositions of
the present invention a 2-phase release profile, where the first
phase releases 10-60% of the active ingredient in about 1 hour and
the second phase releases the rest of the active ingredient, in a
nearly linear fashion, for at least about 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 14, 16, 18, 20, 22, or 24 hours. A pharmaceutically
active agent is released in a "nearly linear" fashion for a
specified period of time if the release rate of the agent does not
change more than 20% during any hour within the specified period of
time.
[0152] In certain embodiments, the composition has an in vitro
dissolution rate measured by standard USP basket method according
to Example 3 of: about 10% to about 60% of the active ingredient
released after 1 hour; about 20% to about 70% of the active
ingredient released after 2 hours; about 30% to about 80% of the
active ingredient released after 4 hours; about 40% to about 90% of
the active ingredient release after 8 hours; and about 50% to about
100% of the active ingredient release after 12 hours. In certain
embodiments, the active ingredient is glucosamine or a
pharmaceutically acceptable salt thereof.
[0153] In certain embodiments, the composition has an in vitro
dissolution rate measured by standard USP basket method according
to Example 3 of: about 0% to about 30% after 2 hours; about 5% to
about 35% after 4 hours, about 10% to about 40% after 8 hours;
about 15% to about 45% after 16 hours; about 20% to about 50% after
24 hours. In certain embodiments, the active ingredient is tramadol
or a pharmaceutically acceptable salt thereof.
[0154] In certain embodiments, the composition has an in vitro
dissolution rate measured by standard USP basket method according
to Example 3 of at most about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or
90% of the active ingredient released after 2, 3, 4, 5, 6, 7, 8, 9,
10, 12, 14, 16, 18, 20, 22, or 24 hours.
[0155] In certain embodiments, the pharmaceutical composition of
the present invention, upon oral administration to a human or
non-human patient in need thereof, provides release of its active
ingredient at such a rate that the blood level of the active
ingredient in the patient is maintained within the therapeutic
range (i.e., at or above minimum effective concentration (MEC) but
below toxic levels) for at least about 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, 48, 72, 96, 120, 144,
or 168 hours.
[0156] The MEC of a pharmaceutically active agent of interest in a
human or non-human patient may be determined using appropriate
techniques known in the art (see, e.g., Grond et al., British
Journal of Clinical Pharmacology 48: 254-7, 1999; and Lehmann et al
Clinical Journal of Pain 6: 212-20, 1990 for determining the MEC of
tramadol in humans).
[0157] In certain embodiments, the composition of the present
invention, when administered orally to a patient in need thereof at
the equivalent daily dose of an immediate release formulation,
provides a plasma concentration of its active ingredient at or
above its minimum effective concentration for a period of time at
least about the same as, or about 2, 3, 4, or 5 times of, that of
the immediate release formulation administered at a daily standard
dose (i.e., the daily dose according to the official product
description for the formulation or the dose approved by a
regulatory authority (e.g., the U.S. FDA) for the formulation).
[0158] E. Physical Form-Pellets
[0159] In certain embodiments, the composition of the present
invention is in the form of pellets.
[0160] The term "pellets" refers to small particles with
approximately uniform shapes and sizes. A "small particle" refers
to a particle of which diameter, length, height, width, or the like
is at most 10 mm (e.g., at most 2, 3, 4, 5, 6, 7, 8, or 9 mm).
Small particles have approximately uniform sizes if the diameter,
length, height, width, or the like of the smallest particle is at
least about one half of the average diameter, length, height,
width, or the like of the particles and if the diameter, length,
height, width, or the like of the largest particle is at most about
twice the average diameter, length, height, width, or the like of
the particles.
[0161] In certain embodiments, the composition of the present
invention is in the form of spherical pellets. The term "spherical
pellet" refers to pellets, beads, particles, spheroids or the like
that are of round or about round shape (i.e., having or approaching
the shape of a small sphere).
[0162] In certain embodiments, the spherical pellets have a smooth
surface texture. Such physical characteristics lead to excellent
flow properties, improved "mouth feel," ease of swallowing and ease
of uniform coating, if required.
[0163] In certain embodiments, the average size (i.e., the average
diameter) of the spherical pellets according to this invention may
be about 0.1 mm to about 3 mm, including any range formed by any
two values between about 0.1 mm and about 3 mm, such as from about
0.5 mm to about 2 mm, or from 0.5 mm to about 1.5 mm. In certain
embodiments, the average size of the spherical pellets is about 1
mm. In certain embodiments, the average size of the spherical
pellets is at least about 0.2, 0.4, 0.5, 0.6, 0.8, 1, 1.2, 1.4, or
1.5 mm.
[0164] In certain embodiments, the sizes of the spherical pellets
according to this invention vary within a range of at most about
5%, 10%, 15%, or 20%, In other words, in certain embodiments, the
diameters of the spherical pellets according to this invention vary
within a range of at most about 5%, 10%, 15%, or 20%. Narrow size
variations provide pellets with sufficient spherical homogeneity so
that they can conveniently be coated for identification, stability,
taste masking, delayed release or sustained or controlled release
applications. Additionally, the narrow size variations allow such
pellets to have a coating of homogeneous thickness.
[0165] In certain embodiments, the size distribution of the
spherical pellets may vary in a statistical manner. For example,
the size distribution may be in a bell-shaped curve wherein about
90% or about 95% of the number of pellets are within a size range
that varies between about 10% to about 20% of the average sizes
mentioned above.
[0166] In certain embodiments, the composition of the present
invention may be in the form of non-spherical pellets (i.e., in the
form other than spherical pellets), such as cylindrical pellets. In
certain embodiments, the cylindrical pellets may a height from
about the same to about 2-3 times of the cylinder diameter. In
certain embodiments, the average cylinder diameter is about 0.1 mm
to about 3 mm, including any range formed by any two values between
about 0.1 mm and about 3 mm, such as from about 0.5 mm to about 2
mm, or from 0.5 mm to about 1.5 mm. In certain embodiments, the
average cylinder diameter of the cylindrical pellets is about 1 mm.
In certain embodiments, the heights of the non-spherical pellets
are about the same.
[0167] The pellets according to the invention have low water
content. In particular embodiments, the water contents in the
pellets is lower than about 5%, 4%, 3%, or 2% of the total weight
of the dry pellets.
[0168] F. Additional Ingredients and Coating
[0169] Optionally, the composition of the present invention may
comprise one or more pharmaceutically acceptable inactive
ingredients, including binders, antioxidants, and colorants.
[0170] Suitable binders include water-soluble hydroxyalkyl
celluloses such as hydroxypropyl cellulose, hydroxypropyl
methylcellulose (HPMC), sodium carboxymethylcellulose sodium (CMC),
or water insoluble polymers, such as pre-gelatinized starch (e.g.,
STARCH 1500M by Colorcon), acrylic polymers or copolymers, or alkyl
celluloses such as ethyl cellulose.
[0171] Suitable antioxidants include butylated hydroxyanisole
(BHA), butylated hydroxytoluene (BHT), vitamin E or ascorbyl
palmitate.
[0172] Suitable colorants may be selected from any FD&C
pigments, dyes or lakes.
[0173] In certain embodiments, these other ingredients may be
present in the pellets at most about 30%, 20%, 10%, or 5% of the
total weight of the dry pellets.
[0174] In certain embodiments, the composition of the present
invention provides sustained release of an active ingredient
without the need of a sustained release barrier coating. In other
words, the matrix of the pellets alone is sufficient in providing
sustained release of the active ingredient.
[0175] The term "sustained release barrier coating" refers to a
coating on a dosage form (e.g., spherical or non-spherical pellets)
that substantially slows the release of the active ingredient of
the dosage form. More specifically, the presence of a sustained
release barrier coating on a dosage form reduces the in vitro
dissolution rate of the active ingredient within the first two
hours (measured by the method disclosed herein) at least by about
50%.
[0176] Uncoated sustained release pellets are preferred over coated
pellets for lower manufacturing cost and scale-up complexity. A
typical sustained release barrier coating for pellets comprises
water-insoluble polymers such as ethylcellulose, which is usually
applied in an organic solvent or in a proprietary aqueous
dispersion (e.g. SURELEASE.RTM. by Colorcon). The organic coating
system requires expensive fireproof or explosion-proof equipment
and facility and environmental protection measures. The proprietary
aqueous dispersion systems are of generally high cost, and because
of the greatly increased surface area, pellets need a much high
amount of coating on a weight basis compared to tablets. For
example, a typical sustained release coating weight for a tablet is
about 1-5% of the total weight of the coated tablets whereas
pellets would need as high as 20-50% of the total weight of the
coated pellets to achieve the same sustained release property
(again due to the greater surface area for the pellets). The cost
of a proprietary aqueous coating dispersion can therefore become a
serious limitation of manufacturing feasibility of a sustained
release pellet products. Moreover, pellet coating is normally
performed using a fluid bed coater, which is more costly to
purchase and to operate than pan coaters conventionally used for
tablets.
[0177] Another reason to prefer sustained release matrix pellets
over coated pellets is the risk of dose dumping. This phenomenon
occurs when there are undesired openings or defects in the coating,
which may be caused during manufacturing or by the patient while
handling the dosage form, or by non-voluntary chewing on it. Small
openings or cracks in the coating mantle causes contact of the
interior with body fluids setting a catastrophic release of the
active causing a serious safety concern.
[0178] In certain embodiments, the composition of the present
invention is not coated with a sustained release barrier coating.
Nevertheless, other functional coatings such as taste masking,
color barrier (such as for identification), or moisture barrier
(such as for improving stability or shelf life) may be applied to
the sustained release pellets of this invention. In another example
where a non-sustained release coating may be needed is the active
ingredient may be too aggressive to the stomach or other parts of
the gastro-intestinal system or may be prone to decomposition by
gastric juices. In such instances, the active ingredient needs to
be kept separated from environmental factors by a suitable
technique such as enteric-coating, e.g., by coating the pellets
with a layer of polymers that is insoluble at the acidic gastric
environment and dissolves only in intestines.
[0179] In certain embodiments, although not required, a sustained
release barrier coating may be applied to the pellets of the
present invention. The presence of the sustained release barrier
coating further slows the release of the active ingredient in the
pellets.
[0180] Suitable sustained release coating materials include
water-insoluble waxes and polymers such as polymethacrylates (e.g.,
the EUDRAGIT.TM., polymers) or water insoluble celluloses, such as
alkyl celluloses (e.g., ethylcellulose). Optionally, water-soluble
polymers such as polyvinylpyrrolidone or water-soluble celluloses
such as hydroxypropylmethyl-cellulose or hydroxypropylcellulose may
be included. Further components that may be added are water-soluble
agents such as polysorbate. In certain embodiment, a suitable
plasticizer may also be added. In certain embodiment, the coating
material sold under the trade name SURELEASE.TM. (Colorcon), which
is a dispersion of ethylcellulose, may be used to form a coating on
the pellets of the present invention.
[0181] G. Exemplary Formulations
[0182] Unless otherwise provided, the exemplary formulations
described in this subsection may comprise any active ingredient,
especially one or more of those specifically described above. In
addition, such exemplary formulations are in the form of pellets
and provide sustained release of the active ingredient (e.g.,
having an in vitro dissolution rate of the active ingredient
measured by standard USP basket method of at most about 90% of the
active ingredient released after 2 hours) without requiring the
presence of a sustained release barrier coating on the pellets.
[0183] In certain embodiments, the composition of the present
invention in the form of pellets comprises: (a) from about 5% to
about 90% of an active ingredient; (b) from about 5% to about 40%
of a wax-like agent; and (c) from about 5% to about 40% of a
spheronizing agent.
[0184] In certain embodiments, the composition of the present
invention in the form of pellets comprises: (a) from about 45% to
about 85% of an active ingredient; (b) from about 5% to about 30%
of a wax-like agent; and (c) from about 5% to about 30% of a
spheronizing agent.
[0185] In certain embodiments, the composition of the present
invention in the form of pellets comprises: (a) from about 50% to
about 75% of an active ingredient; (b) from about 10% to about 30%
of a wax-like agent; and (c) from about 5% to about 20% of a
spheronizing agent.
[0186] In certain embodiments, the composition of the present
invention in the form of pellets comprises: (a) from about 60% to
about 65% of an active ingredient; (b) from about 10% to about 30%
of a wax-like agent; and (c) from about 5% to about 20% of a
spheronizing agent, in certain embodiments, the composition
comprises: (a) from about 45% to about 85% of an analgesic or a
pharmaceutically acceptable salt thereof; (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., hydrogenated
cottonseed oil); (c) from about 5% to about 20% of microcrystalline
cellulose; and (d) from about 1% to about 10% pregelatinized
starch.
[0187] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of a dietary supplement or a
pharmaceutically acceptable salt thereof; (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., hydrogenated
cottonseed oil); (c) from about 5% to about 20% of microcrystalline
cellulose; and (d) from about 1% to about 10% pregelatinized
starch.
[0188] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an antiviral agent or a pharmaceutically
acceptable salt thereof; (b) from about 5% to about 30% of
hydrogenated vegetable oil (e.g., hydrogenated cottonseed oil); (c)
from about 5% to about 30% of microcrystalline cellulose; and (d)
from about 1% to about 10% pregelatinized starch.
[0189] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an anti-infective agent or a
pharmaceutically acceptable salt thereof, (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., hydrogenated
cottonseed oil), (c) from about 5% to about 30% of microcrystalline
cellulose, and (d) from about 1% to about 10% pregelatinized
starch.
[0190] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an antacid, (b) from about 1% to about
30% of hydrogenated vegetable oil (e.g., hydrogenated cottonseed
oil), (c) from about 5% to about 30% of microcrystalline cellulose,
and (d) from about 1% to about 10% pregelatinized starch.
[0191] In certain embodiments, the composition comprises: (a) from
about 45% to about 90% of a high-dose pharmaceutically active
agent, (b) from about 5% to about 40% of hydrogenated vegetable oil
(e.g., hydrogenated cottonseed oil), (c) from about 5% to about 40%
of microcrystalline cellulose, and (d) from about 1% to about 10%
pregelatinized starch.
[0192] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of an insect growth regulator or a
pharmaceutically acceptable salt thereof; (b) from about 5% to
about 30% of hydrogenated vegetable oil (e.g., hydrogenated
cottonseed oil); (c) from about 5% to about 30% of microcrystalline
cellulose; and (d) from about 1% to about 10% pregelatinized
starch.
[0193] In certain embodiments, the composition comprises; (a) from
about 60% to about 65% of tramadol or a pharmaceutically acceptable
acid-addition salt thereof (e.g., tramadol hydrochloride); (b) from
about 15% to about 30% of hydrogenated vegetable oil (e.g.,
hydrogenated cottonseed oil); and (c) from about 5% to about 15% of
microcrystalline cellulose.
[0194] In certain embodiments, the composition comprises: (a) from
about 60% to about 65% of glucosamine or a pharmaceutically
acceptable acid-addition salt thereof (e.g., glucosamine
hydrochloride); (b) from about 15% to about 30% of hydrogenated
vegetable oil (e.g., hydrogenated cottonseed oil); and (c) from
about 5% to about 15% of microcrystalline cellulose.
[0195] In certain embodiments, the composition comprises: (a) from
about 60% to about 65% of azithromycin or a pharmaceutically
acceptable acid-addition salt thereof (e.g., azithromycin
hydrochloride); (b) from about 15% to about 30% of hydrogenated
vegetable oil (e.g., hydrogenated cottonseed oil); and (c) from
about 5% to about 15% of microcrystalline cellulose.
[0196] In certain embodiments, the composition comprises: (a) from
about 60% to about 65% of acyclovir or valacyclovir; (b) from about
15% to about 30% of hydrogenated vegetable oil (e.g., hydrogenated
cottonseed oil); and (c) from about 5% to about 15% of
microcrystalline cellulose.
[0197] In certain embodiments, the composition comprises: (a) from
about 45% to about 85% of a combination of aluminum hydroxide and
magnesium hydroxide in a 3:1, 2:1, 1:1, 1:2, or 1:3 ratio, (b) from
about 5% to about 20% of hydrogenated vegetable oil (e.g.,
hydrogenated cottonseed oil), (c) from about 5% to about 15% of
microcrystalline cellulose, and (d) about 1 to about 10% of
pregelatinized starch.
[0198] In certain embodiments, the composition comprises: (a) from
about 40% to 65% of aluminum hydroxide, (b) from about 20% to about
30% magnesium hydroxide, (c) from about 5% to about 15% of
hydrogenated vegetable oil (e.g., hydrogenated cottonseed oil); and
(d) about 5% to about 15% of microcrystalline cellulose, and (e)
about 1 to about 10% of pregelatinized starch.
[0199] In certain embodiments, the composition comprises: (a) from
about 50% to 75% of sodium phosphate tribase, (b) from about 10% to
30% of hydrogenated vegetable oil (e.g., hydrogenated cottonseed
oil), (c) from about 5% to about 15% of microcrystalline cellulose,
and (d) about 1% to about 10% of pregelatinized starch.
[0200] In certain embodiments, the present invention provides a
mixture of one of the two compositions described above in this
subsection that contain both aluminum hydroxide and magnesium
hydroxide in the form of pellets with the composition described
above in this subsection that contains sodium phosphate tribase, in
certain embodiments, the weight ratio of the composition that
contains both aluminum hydroxide and magnesium hydroxide to the
composition that contains sodium phosphate tribase is about
9:1.
II. Dosage Forms
[0201] In another aspect, oral dosage forms that comprise the
compositions disclosed herein are provided.
[0202] The term "oral dosage form" refers to a device that
collectively delivers, by oral ingestion, the desired amount of an
active ingredient, to achieve a desired dose of the active
ingredient. Typically, the oral dosage form is a powder for oral
suspension, a unit dose packet or sachet, a tablet, or a
capsule.
[0203] In certain embodiments, the pellets of this invention may be
mixed with a vehicle and packaged in a container such as a screw
cap bottle. Prior to dosing, the mixture is added with water or
another liquid and shaken to form an "oral suspension." In this
oral suspension, the pellets containing the active ingredient may
be (a) completely suspended in the vehicle, or (b) partially
suspended in the vehicle and partially in solution with the
vehicle.
[0204] The term "vehicle" refers to a mixture of pharmaceutically
acceptable ingredients put together to facilitate the suspension of
pellets and improve the taste of an oral suspension. A vehicle
useful in this invention may contain suspending agents, anticaking
agents, fillers, sweeteners, flavorants, colorants, and/or
lubricants.
[0205] Examples of suspending agents or thickeners include xanthan
gum, starch, guar gum, sodium alginate, carboxymethyl cellulose,
sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl
methyl cellulose, polyacrylic acid, silica gel, aluminum silicate,
magnesium silicate, and titanium dioxide.
[0206] Examples of anticaking agents or fillers include colloidal
silicon oxide and lactose.
[0207] Other conventional excipients may be employed in the
compositions of this invention, including those excipients
well-known in the art. Generally, excipients such as pigments,
lubricants, sweeteners, flavorants, and so forth may be used for
customary purposes and in typical amounts without adversely
affecting the properties of the compositions.
[0208] In certain embodiments, the dosage form may be packaged in a
bottle, packet, pouch, sachet, or capsule.
[0209] In certain embodiments, the dosage form comprises the active
ingredient at a dose of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10 gram per dose.
[0210] In certain embodiments, the invention provides unitary
dosage forms that comprise tramadol hydrochloride pellets as
described herein in an amount so that the dosage forms contain an
effective amount of tramadol hydrochloride. In certain embodiments,
such dosage forms may contain from about 10 mg to about 100 mg
tramadol hydrochloride per unit, such as from about 15 mg to about
75 mg of tramadol hydrochloride per unit, or from about 25 mg to
about 65 mg of tramadol hydrochloride per unit.
[0211] In certain embodiments, the invention provides unitary
dosage forms that comprise glucosamine hydrochloride pellets as
described herein in an amount such that the dosage forms contain an
effective amount of glucosamine hydrochloride. In certain
embodiments, such dosage forms may contain from about 1,000 mg to
about 10,000 mg glucosamine hydrochloride per unit, such as from
about 1,500 mg to about 2,500 mg of glucosamine hydrochloride per
unit for a human patient, or from about 5,000 mg to about 50,000 mg
of glucosamine hydrochloride per unit for an equine patient.
[0212] In certain embodiments, the invention provides unitary
dosage forms that comprise azithromycin or a pharmaceutical salt
thereof pellets as described herein in an amount such that the
dosage forms contain an effective amount of azithromycin. In
certain embodiments, such dosage forms may contain from about 1,000
mg to about 3,000 mg azithromycin per unit, such as from about
1,500 mg to about 2,500 mg of azithromycin per unit, or about 2,000
mg of azithromycin per unit.
[0213] In certain embodiments, the mixture of the pellets of the
present invention and a vehicle may be mixed with water to form an
oral suspension. In certain other embodiments, other liquids may be
used instead of water, such as coffee, tea, milk, and various
juices. In certain embodiments, the mixture of water mixed and
other excipients, including surfactants, thickeners, suspending
agents, and the like, may be used to prepare an oral
suspension.
[0214] Depending upon the solid-to-liquid ratio, the sustained
release pellets dosage form may also be in the form of a paste,
slurry or suspension.
[0215] In certain embodiments, the dosage form is for single dose
use. "Single dose," as used herein, refers to administering only
one dose of an active ingredient in the full course of therapy.
[0216] In certain embodiments, the dosage form, upon oral
administration to a patient in need thereof, provides a plasma
concentration of the active agent in the patient at or above its
minimum effective concentration for at least about 2, 4, 6, 8, 10,
12, 14, 16, 18, 20, 24, 36, 48, 72, 96, 120, 144, or 168 hours.
[0217] In certain embodiments, the dosage form, upon oral
administration to a patient in need thereof, provides a plasma
concentration of the active agent in the patient at or above its
minimum effective concentration for a period of time that is at
least about 2, 3, 4, or 5 times of that of an immediate release
formulation administered at a standard dose.
[0218] In certain embodiments, the dosage form is suitable for
administration to a patient in need thereof at, or no more than,
once or twice per day, once per two, three, four, five, six, seven
days, once per one, two, three, or four weeks, or once per
treatment.
III. Methods of Making Compositions
[0219] In another aspect, the present invention provides a method
for making the compositions and dosage forms described herein.
[0220] For example, in one aspect, the present application provides
a method for making spherical or non-spherical pellets comprising
(i) an active ingredient; (i) a wax-like agent; and (iii) a
spheronizing agent, the method comprising: (a) preparing a mixture
of the active ingredient, the wax-like agent, the spheronizing
agent, and a liquid; (b) extruding said mixture to obtain an
extrudate; (c) spheronizing the extrudate to form spherical pellets
or fragmenting the extrudate to form non-spherical pellets; (d)
drying the spherical pellets; and (e) heating the dry pellets to a
temperature higher than the melting point of the wax-like
agent.
[0221] In certain embodiments, a method for making sustained
release spherical pellets of the present invention is provided,
comprising:
[0222] (i) mixing dry powder components comprising an active
ingredient, a wax-like sustained releasing agent, a spheronizing
agent and other optional ingredients with a liquid to form a
homogenous and evenly wetted mass.
[0223] (ii) extruding the wet mass into cylindrical "spaghetti
like" strands ("extrudates"),
[0224] (iii) spheronizing the extrudates, which fragments the
strands into short cylinders and roll-forms them into spheres,
[0225] (iv) drying the spheres, and
[0226] (v) heating the dry spheres at a temperature exceeding the
melting point of the wax-like sustained release agent.
[0227] In certain related embodiments, a method for making
sustained release spherical pellets of the present invention
comprises steps (i) to (iv) as described above, but not step (v) as
described above.
[0228] In certain embodiments, spherical pellets may be produced by
adding water to a dry blend of an active ingredient, a wax-like
agent, a spheronizing agent, and other optional ingredients and
extruding the thus formed wet mass through a small orifice
(typically approx. 1 mm). Then the extruded material is placed into
a spheronizer where it is spun at high speed. During this step, the
extrudates break and round into pellets, the size being determined
by the size of the extrusion orifice.
[0229] To produce extrudates suitable for subsequent
spheronization, the wet mass need have the proper cohesiveness and
plasticity to undergo plastic deformation and flow through the
orifice as cylindrical extrudates. Furthermore, the subsequent
spheronization process requires the extrudates to be friable enough
to break into short lengths, but sufficiently plastic for the short
lengths to form into spheres and not so wet or sticky that the
spheres agglomerate and become oversized, or stick to the spin
plate of the spheronizer.
[0230] The ratios of the wax-like agent to the spheronizing agent
as well as the water content in the wet extrudates may be adjusted
to produce wet extrudates suitable for spheronization. In certain
embodiments, the ratio of the wax-like agent to the spheronizing
agent is in a range from about 3:1 to about 1:14 by weight
(including any range formed by any two values between about 3:1 to
about 1:14), the water content in the wet extrudates in the range
of about 30% to about 90% (including any range formed by any two
values between about 30% and about 90%) based on the weight of the
wet mass.
[0231] In certain embodiments, the wet mass is produced with an
organic solvent or its mixture with water. The organic solvent may
be selected based on Its ability to form a spheronizable wet mass,
to render a low toxicity, and to be removed by the drying steps to
low residual level. To select a safe solvent, Class 2 and Class 3
Solvents as listed in the US FDA "Guidance for Industry, Q3C
Impurities: Residual Solvents" may be referenced. Examples of such
solvents include:
TABLE-US-00002 PDE Concentration Limit Solvent (mg/day) (ppm)
Acetonitrile 4.1 410 Chlorobenzene 3.6 360 Chloroform 0.6 60
Cyclohexane 38.8 3,880 1,2-Dichloroethene 18.7 1,870
Dichloromethane 6.0 600 1,2-Dimethoxyethane 1.0 100
N,N-Dimethylacetamide 10.9 1,090 N,N-Dimethylformamide 8.8 880
1,4-Dioxane 3.8 380 2-Ethoxyethanol 1.6 160 Ethyleneglycol 6.2 620
Formamide 2.2 220 Hexane 2.9 290 Methanol 30.0 3,000
2-Methoxyethanol 0.5 50 Methylbutyl ketone 0.5 50 Methylcyclohexane
11.8 1,180 N-Methylpyrrolidone 5.3 530 Nitromethane 0.5 50 Pyridine
2.0 200 Sulfolane 1.6 160 Tetrahydrofuran 7.2 720 Tetralin 1.0 100
Toluene 8.9 890 1,1,2-Trichloroethene 0.8 80 Xylene.sup.1 21.7
2,170
TABLE-US-00003 Acetic acid Heptane Acetone Isobutyl acetate Anisole
Isopropyl acetate 1-Butanol Methyl acetate 2-Butanol
3-Methyl-1-butanol Butyl acetate Methylethyl ketone
tert-Butylmethyl ether Methylisobutyl ketone Cumene
2-Methyl-1-propanol Dimethyl sulfoxide Pentanel Ethanol 1-Pentanol
Ethyl acetate 1-Propanol Ethyl ether 2-Propanol Ethyl formate
Propyl acetate Formic acid
[0232] In certain embodiments, mixtures of propylene glycol and
water, ethanol and water, isopropanol and water are used to produce
the wet mass.
[0233] In certain embodiments, the wax-like agent content may be in
the range of about 5% to about 50% of the weight of the dry pellets
(i.e., pellets produced by performing steps (i) to (v) or by
performing steps (i) to (iv) if step (v) is not performed). In
certain embodiments, the wax-like agent is at most about 30% or 25%
of the weight of the dry pellets. In certain embodiments, the
wax-like agent is about 20% of the weight of the dry pellets.
[0234] In order for a wax-like sustained release agent to provide a
sustained release of the active ingredient in the pellet form, the
pellets need be dried and heated at a temperature exceeding the
melting point of the wax-like sustained release agent. The present
invention may utilize a fluid-bed processor to dry the pellets at
about 40.degree. C. (hot air temperature) to remove the majority
amount of the water ("the first stage of drying") and heat the dry
pellets at a temperature which is about 15 to 20.degree. C. higher
than the melting point of the wax-like agent (e.g., 75.degree. C.
hot air temperature) to remove the tightly bound water and to
impart the desired sustained release property to the pellets ("the
second stage of drying").
[0235] The drying/heating process may be applied in two consecutive
steps; the first stage of drying is primarily to remove water and
to cause the pellet to sufficiently harden to allow for more
rigorous heating in the second stage of drying. A lower temperature
(about 40.degree. C., which is below the melting point of the
wax-like agent) is usually sufficient for the drying purpose and is
preferred for the stability of the active ingredient. The drying
time of the first stage may vary from 10 minutes to several hours
depending upon the batch size and efficiency of the dryer. The end
point for the first stage of drying is water content of less than
about 5% to about 10% relative to the total weight of the pellets
after the first stage of drying.
[0236] The second stage of drying further reduces the water content
in the pellets to less than about 2% relative to the total weight
of the resulting pellets. In certain embodiments, the second stage
of drying is performed at a temperature about 15.degree. C. to
about 20.degree. C. higher than the melting point of the wax-like
agent to remove the tightly bound water. The drying time of the
second stage drying may vary from 15 minutes to several hours
depending upon the batch size and efficiency of the dryer. An even
higher temperature may be applied so long that it does not cause
deformation or agglomeration of pellets or thermal degradation of
the active or other ingredients in the pellets. In addition to
lowering the water content to less than about 2% relative to the
total weight of the resulting pellets, the end point for the second
stage drying is also for the pellets to reach their targeted
sustained release profile.
[0237] Not wishing to be bound by any theory, the second stage of
drying, which resembles a thermal annealing treatment, is believed
to cause a partial melting of wax-like sustained release agent in
the pellets to allow for more intimate incorporation and embedment
of the active ingredient in the matrix of the wax-like agent
without any significant deformation or agglomeration of the
pellets. The melting and congealing of the wax-like sustained
release agent may also help sealing the pores in the pellets due to
the removal of water and thus reduce the surface area of the
pellets. Pellets prepared by the same method described herein but
without the second drying step exhibited significantly faster drug
release (see, Example 17).
[0238] In certain embodiments, the drying process is one continuous
step where the temperature is ramped from about room temperature to
about 15.degree. C. to about 20.degree. C. above the melting point
of the wax-like sustained release agent in a timed program.
[0239] In certain embodiments, the drying and heating of pellets
may be performed in a fluid bed process, convection or microwave
oven.
[0240] In other embodiments, a method for making sustained release
non-spherical pellets of the present invention is provided,
comprising:
[0241] (i) mixing dry powder components comprising an active
ingredient, a wax-like sustained releasing agent, spheronizing
agent and optional other ingredients with a liquid to form a
homogenous and evenly wetted mass,
[0242] (ii) extrudating the wet mass into cylindrical "spaghetti
like" strands ("extrudates"),
[0243] (iii) fragmenting the extrudates into pellets of short
cylindrical lengths,
[0244] (iv) drying the pellets, and
[0245] (v) heating the dry pellets at a temperature exceeding the
melting point of the wax-like sustained release agent.
[0246] In certain related embodiments, a method for making
sustained release non-spherical pellets of the present invention
comprises steps (i) to (iv) as described above, but not step (v) as
described above.
[0247] Above steps (i), (ii), (iv), and (v) for making
non-spherical pellets may be performed similar to those described
above for making spherical pellets.
[0248] As to step (iii), in certain embodiments, a planetary mixer
(e.g., a Hobart mixer) equipped with a wire mixing head (e.g., "egg
beater") or a cutter may be used to break the wet extrudates into
cylindrical pellets the height of which may vary from about the
same to about 2 to 3 times of cylinder diameter.
IV. Methods of Using Compositions and Dosage Forms
[0249] In one aspect, the present invention provides methods for
using the pharmaceutical compositions and dosage forms described
herein. Such pharmaceutical compositions may be used for treating
or preventing (i.e., reducing the risk of) diseases or disorders
that the pharmaceutically active agents in the compositions are
suitable for treating or preventing.
[0250] The diseases or disorders include, but are not limited to,
pains, joint weakness, bacterial or viral infections, lipid
disorder, diabetes, vitamin or mineral deficiency, gastrointestinal
ulcer or other disorders, asthma, and parasite infestation.
[0251] In certain embodiments, the present invention provides a
method for reducing pain comprising administering orally to a
patient in need thereof a pharmaceutical composition or dosage form
as described herein that comprises an effective amount of an
analgesic or a pharmaceutically acceptable salt thereof.
[0252] In certain embodiments, the present invention provides a
method for reducing pain comprising administering orally to a
patient in need thereof a pharmaceutical composition or dosage form
as described herein that comprises an effective amount of tramadol,
tramadol HCl or another pharmaceutically acceptable salt.
[0253] In certain embodiments, the present invention provides a
method for reducing joint discomfort or increasing joint
flexibility comprising administering orally to a patient in need
thereof a pharmaceutical composition or dosage form as described
herein that comprises an effective amount of glucosamine,
glucosamine sulfate, glucosamine HCl or another pharmaceutically
acceptable salt.
[0254] In certain embodiments, the present invention provides a
method for reducing joint discomfort or increasing joint
flexibility comprising administering orally to a patient in need
thereof a pharmaceutical composition or dosage form as described
herein that comprises an effective amount of glucosamine HCl and
chondroitin sulfate.
[0255] In certain embodiments, the present invention provides a
method for reducing pain or fever that comprises administering
orally to a patient in need thereof a pharmaceutical composition or
dosage form as described herein comprising an effective amount of
acetaminophen.
[0256] In certain embodiments, the present invention provides a
method for treating or preventing (i.e., reducing the risk of)
seizure or reducing neuropathic pain that comprises administering
orally to a patient in need thereof a pharmaceutical composition or
dosage form as described herein comprising an effective amount of
gabapentin.
[0257] In certain embodiments, the present invention provides a
method for lowering blood sugar level comprising administering
orally to a patient in need thereof a pharmaceutical composition or
dosage form as described herein that comprises an effective amount
of metformin hydrochloride.
[0258] In certain embodiments, the present invention provides a
method for treating or preventing dietary deficiency that comprises
administering orally to a patient in need thereof a pharmaceutical
composition or dosage form as described herein comprising an
effective amount of dietary supplement.
[0259] In certain embodiments, the present invention provides a
method for treating or preventing viral infection that comprises
administering orally to a patient in need thereof a pharmaceutical
composition or dosage form as described herein comprising an
effective amount of an anti-viral agent.
[0260] In certain embodiments, the present invention provides a
method for treating or preventing bacterial infection that
comprises administering orally to a patient in need thereof a
pharmaceutical composition or dosage form as described herein
comprising an effective amount of an anti-infective agent or a
pharmaceutically effective salt thereof.
[0261] In certain embodiments, the present invention provides a
method for treating or preventing bacterial infection that
comprises administering orally to a patient in need thereof a
pharmaceutical composition or dosage form as described herein
comprising an effective amount of an antibiotic.
[0262] In certain embodiments, the present invention provides a
method for treating or preventing a gastrointestinal ulcer or
disorder that comprises administering orally to a patient in need
thereof a pharmaceutical composition or dosage form as described
herein comprising an effective amount of an antacid agent.
[0263] In certain embodiments, the method for treating or
preventing gastrointestinal ulcer or disorder comprises
administering orally to a patient in need thereof a mixture of a
composition that comprises aluminum hydroxide and magnesium
hydroxide described herein and a composition that comprises sodium
phosphate tribase described herein. In certain embodiments, the
ratio of the total weight of aluminum hydroxide and magnesium
hydroxide to sodium phosphate tribase is about 9:1. In certain
embodiments, the present invention provides a method for treating
or preventing parasite and/or pest infestation that comprises
administering orally to a patient in need thereof a pharmaceutical
composition or dosage form as described herein comprising an
effective amount of an insect growth regulator.
[0264] Patients in need of treatment or prevention of a disease or
disorder include both human patients (e.g., adult human patients)
and non-human patients (e.g., dogs, cats, horses, and other pets or
farm animals).
[0265] An "effective amount" refers to the amount of a
pharmaceutically active agent effective in treating or preventing a
disease or disorder. Such amount may be determined by appropriate
methods known in the art. For instance, a sufficient amount of an
analgesic or analgesics (such as tramadol and acetaminophen) in a
pharmaceutical composition of the present invention may be
determined using various methods for measuring analgesia, such as
those described in U.S. Patent Application Publication No.
20050089558, Collier of al., Br, J. Pharmacol. 32: 295, 1968;
D'Amour et al., J. Pharmacol, Exp. Ther. 72: 74, 1941; and
Hargreaves et al., Pain 32:77, 1988.
[0266] In certain embodiments, the pharmaceutical composition or
dosage form may be combined with food or animal feed before
administration.
[0267] The following examples are provided without any intent to
limit the scope of the instant invention.
EXAMPLES
Example 1
Preparation of Sustained Release Spherical Pellets of Glucosamine
Hydrochloride
[0268] A dry blend of 325 g of glucosamine hydrochloride (by
Pharmore), 100 g of hydrogenated cottonseed oil, NF (STEROTEX.RTM.,
by Abitec Corp.), 45 g of microcrystalline cellulose, NF
(AVICEL.RTM. by FMC Biopolymers), and 30 g of pregelatinized starch
(STARCH 1500.RTM. by Colorcon Corp.) was wet massed with
approximately 155 g of de-ionized water using a planetary mixer
(Hobart) and extruded through a small orifice (1.2 mm) using an
Fuji Pauda Multi-Gran model MG-55 extruder with a dome-die screen.
The extruded material (extrudates) was placed into a spheronizer
(Fuji Paudal Marumerizer QJ-230T-1) where it was spun at 1000 RPM
for about 1 to 10 minutes. During this step, the extrudate broke
and rounded into pellets, the size of which being determined by the
size of the extrusion orifice. The extrudate broke easily and
produced round pellets of uniform size, and no sticking was
observed in the spheronizer. The wet spherical pellets were placed
in open-air area at room temperature for about 16 hours,
transferred into a fluid bed dryer (Labline Model 23850), dried at
40.degree. C. for 15 hours and then heated at 75.degree. C. for 15
minutes. The dry pellets were sieved through a 12-mesh sieve to
remove large particles and a 32-mesh sieve to remove fine
particles. The particles with size between 0.5 mm and 1.8 mm in
diameter were collected. The process yielded 96.6% dry pellets. The
pellets were spherical in shape with a moisture content of 0.46%
w/w.
[0269] About 84 milligrams of the resulting spherical glucosamine
pellets were weighed out and transferred into a 50 mL volumetric
flask, and simulated gastric fluid (USP, without enzymes) was added
to the 50-mL volume mark. The content was mixed well and sonicated
in a bath sonicator to extract glucosamine from the pellets. The
supernatant was removed and injected into an HPLC under the
following conditions:
[0270] Column: Hamilton RCX-10, M 250.times.4.6 mm
[0271] Mobile phase: 10 mM NaOH in water
[0272] Flow: 1.2 mL/min
[0273] Column temperature: 30 deg C.
[0274] Detection wavelength: 215 nm
[0275] The content of glucosamine hydrochloride in the pellets
produced as described above was determined to be 62.2% w/w.
Example 2
Preparation of Sustained Release Non-Spherical (Cylindrical)
Pellets of Glucosamine Hydrochoride
[0276] A dry blend of 3250 g of glucosamine hydrochloride (by
Pharmore), 1000 g of hydrogenated cottonseed oil, NF (STEROTEX.RTM.
by Abitec Corp.), 450 g of microcrystalline cellulose, NF
(AVICEL.RTM. by FMC Biopolymers), and 300 g of pregelatinized
starch (STARCH 1500.RTM. by Colorcon Corp) was wet massed with
approximately 1500 g of de-ionized water using a planetary mixer
(Hobart) and extruded through a small orifice (1.2 mm) using an
Fuji Paudal Multi-Gran model MG-55 extruder with a dome-die screen.
The extruded material (extrudate) was placed into a 6-quart mixer
(KitchenAid mixer with an egg mixing apparatus) where it was spun
at about 1000 RPM for about 1-2 minute. During this step the
extrudate broke into small cylindrical pellets (non-spherical), the
height of the cylinders being close to the diameter of the
extrudate. The extrudate broke easily and produced cylindrical
pellets of fairly uniform size and no sticking was observed in the
spheronizer. The wet spherical pellets were placed in open-air area
at room temperature for about 16 hours, transferred into a fluid
bed dryer (Labline Model 23850), dried at 40.degree. C. for 15
hours and then heated at 75.degree. C. for 15 minutes. The dry
pellets were sieved through a 12-mesh sieve to remove large
particles and a 32-mesh sieve to remove fine particles. The
particles with size between 0.5 mm and 1.8 mm in diameter were
collected. The process yielded 97.2% dry pellets.
[0277] The thus prepared non-spherical pellets were cylindrical in
shape with a moisture content of 0.41% w/w and glucosamine
hydrochloride content of 65.7% w/w. The pellets were mixed with
0.1% molasses flavor for voluntary consumption by horeses.
Example 3
Dissolution Rate
[0278] The in vitro dissolution rate of the preparation of Example
1 was measured according to the standard USP Basket Method
(Apparatus type 1) using the following conditions:
TABLE-US-00004 Sample size: 1 g pellets per basket Speed: 50 RPM
Medium: Simulated gastric fluid SGF per USP without enzyme Volume:
500 mL/vessel Temperature: 37.degree. C. Concentration analysis:
HPLC
[0279] Representative dissolution profiles from spherical and
non-spherical pellets are shown in FIG. 1 and the general profile
can be described as follows:
About 40% active ingredient released after 1 hour, About 50% active
ingredient released after 2 hours, About 60% active ingredient
released after 4 hours, About 70% active ingredient released after
8 hours, About 80% active ingredient released after 12 hours, About
90% active ingredient released after 18 hours, and About 100%
active ingredient released after 24 hours.
[0280] Other commercially available multiparticulate formulations
of glucosamine have also been tested using the same method and
results are shown in FIG. 2. The release was completed (100%
release) in about or less than 3 hours for the commercial products
compared to 24 hours for the pellets prepared according to Example
1.
Example 4
Stability of Active Ingredient in Pellets
[0281] Glucosamine pellets prepared according to Example 2 were
placed in a sealed container and stored at 25.degree. C./60% RH for
2 months. The pellets were tested for contents of active ingredient
and dissolution rates using the methods described in Examples 2 and
3. The results of active ingredient contents are represented in
table below and dissolution profiles in FIG. 3. The results show
that glucosamine is stable in the pellets for at least two
months.
TABLE-US-00005 Glucosamine HCl Recovered over the Initial Conc. (%)
Initial 2 Month Storage 100 98.1
Example 5
Preparation of Sustained Release Spherical Pellets Containing
Glucosamine Hydrochloride, Chondroitin Sulfate, Ascorbic Acid and
Manganese Sulfate
[0282] A dry blend of 50 g of glucosamine hydrochloride (by
Pharmore), 4.7 g chondroitin sulfate (by Maypro), 1 g calcium
ascorbate (by Zila) and 0.3 g manganese sulfate (by Prince Agri),
0.1 g molasses flavor powder (by Gold Coast), 20 g of hydrogenated
cottonseed oil, NF (STEROTEX.RTM., by Abitec Corp.), and 24 g of
microcrystalline cellulose, NF (AVICEL.RTM. by FMC Biopolymers) was
wet massed with approximately 30 g of de-ionized water using a
planetary mixer (KitchenAid) and extruded through a small orifice
(1.2 mm) using an Fuji Paudal Multi-Gran model MG-55 extruder with
a dome-die screen. The extruded material (extrudates) was placed
into an spheronizer (Fuji Paudal Marumerizer QJ-230T-1) where it
was spun at 1500 RPM for about 1 to 2 minutes. During this step,
the extrudate broke and rounded into pellets, the size being
determined by the size of the extrusion orifice. The extrudate
broke easily and produced round pellets of uniform size, and no
sticking was observed in the spheronizer. The wet spherical pellets
were placed in open-air area at room temperature for about 3 hours,
transferred into a fluid bed dryer (Labline Model 23850), dried at
40.degree. C. for 10 hours and then heated at 75.degree. C. for 10
minutes. The thus prepared spherical pellets were spherical in
shape with moisture content of 0.46% w/w. The in vitro dissolution
profile of glucosamine is shown in FIG. 4.
Example 6
Preparation of Tramadol Hydrochloride Spherical Pellets
[0283] A series of spherical pellets containing a highly water
soluble tramadol hydrochloride were prepared to contain the
following compositions:
TABLE-US-00006 Weight percent based on total solids formulation
code Component F-8 F-9 F-10 F-11 F-12 F-13 F-15 F-16 Tramadol HCl
3.3 3.3 3.3 3.3 15.0 20.0 25.0 30 Cation 13.3 13.3 13.3 13.3 45.0
40.0 40.0 40 exchange resin Micro- 73.3 63.3 36.7 53.3 40.0 40.0
35.0 30 crystalline cellulose Hydrogenated 10.0 20.0 13.3 30 0 0 0
0 cottonseed oil
[0284] Tramadol HCl was first mixed with cation exchange resin
(Amberlite IRP69 by Rohm Haas) and the mixture was suspended and
mixed in de-ionized water to allow for the binding of tramadol to
the resin. The suspension was wet massed with microcrystalline
cellulose and hydrogenated cottonseed oil, extrudated, spheronized,
dried and heated according to the method described in Example
1,
[0285] In vitro dissolution profiles are shown in FIG. 5. The
spherical pellets prepared according to this invention F-8, F-9,
F-10 and F-11) exhibited extensively sustained release
characteristics with more than 24 release duration observed.
Pellets prepared without hydrogenated cottonseed oil (F-11, F-12,
F-13, F-15 and F-16), on the other hand, released tramadol in about
4 hours and is regarded inappropriate for once-a-day dosing. This
study indicates feasibility of providing a once-a-day formulation
for tramadol using the sustained release pellets process and
formulation according to this invention. It further demonstrates
the necessity of the wax-like agent in such sustained release
pellets formulations.
Example 7
Preparation of Azithromycin Sustained Release Spherical Pellets
[0286] A dry blend of 100 g of azithromycin, USP (by Polymed), 50 g
of hydrogenated cottonseed oil, NF (STEROTEX.RTM., by Abitec
Corp.), 28 g of microcrystaline cellulose, NF (AVICEL.RTM. by FMC
Biopolymers), 0.04 g BHA and 22 g of pregelatinized starch (STARCH
1500.RTM. by Colorcon Corp.) was wet massed, extrudated,
spheronized, dried and heated according to the method described in
Example 1.
[0287] The thus prepared pellets were spherical in shape with a
moisture content of 0.5% w/w and azithromycin content of 52.3%
w/w.
Example 8
Preparation of Azithromycin Spherical Pellet's for Oral
Suspension
[0288] A vehicle was prepared by mixing 946 g sucrose, NF, 3.2 g
hydroxypropyl cellulose, NF, 3.3 g xanthan gum, NF, 98 g colloidal
silicon dioxide, NF, 19.5 g titanium dioxide, USP, 6.9 cherry
flavoring powder, and 11.3 g banana flavoring powder.
[0289] Four grams of azithromycin pellets prepared according to
Example 7 (containing 2 g azithromycin) were mixed with 20 g of the
vehicle in a 100 mL plastic bottle to provide a powder blend
formulation for oral suspension. This powder blend forms a uniform
suspension upon manual shaking after addition of 60 mL water. The
thus formed suspension provides pleasing taste and mouth feel and
is easy to be swallowed.
[0290] The powder blend thus prepared was tested for in vitro
dissolution and compared with a commercial sustained release
suspension product (ZMAX.TM., azithromycin extended release for
oral suspension by Pfizer) using the method as described in U.S.
Pat. No. 6,984,403. ZMAX.RTM. (azithromycin extended release) for
oral suspension is a single-dose, liquid antibiotic used to treat
certain types of mild to moderate bacterial infections including
Acute bacterial sinusitis (ABS) and Community-acquired pneumonia
(CAP). ZMAX.TM. provides a full course of treatment in a single,
high dose (i.e., the patient takes just one dose, one time).
[0291] The results of the in vitro dissolution comparison between
the powder blend according to this example and ZMAX.TM. are shown
in FIG. 6. They demonstrate that the sustained release pellets
prepared according to this invention is capable of providing a
sustained release profile of azithromycin comparable to other
extended release suspension, such as ZMAX.TM., which is prepared
using a very different composition and method. It is also indicated
that a high dose (2 g or more) can be readily dosed in the powder
blend containing spherical pellets as described in this
example.
Example 9
Stability of Azithromycin Spherical Pellets for Oral Suspension
[0292] Stability of azithromycin in spherical pellets for oral
suspension according to Examples 7 and 8 was evaluated by measuring
for appearance, pH, moisture content, drug content and purity, and
in vitro dissolution of azithromycin. The pellets were packaged
with the vehicle (as described in Example 8) in high density
polyethylene bottles, and the bottles were stored in 25.degree.
C./60% RH and 40.degree. C./75% RH stability chambers.
[0293] The drug content in the azithromycin spherical pellets for
oral suspension was measured using an HPLC method under the
following conditions:
TABLE-US-00007 Column: a 5-micron reverse-phase C-18 column with
4.6 mm diameter and 100 mm length Mobile phase A: 0.05%
trifluoroacetic acid in water Mobile phase B: 0.05% trifluoroacetic
acid in acetonitriles Column temperature: 40.degree. C. Flow rate:
0.7 mL/min Detection: 205 nm
[0294] The tables below show the stability test results. The
results indicated that the azithromycin spherical pellets for oral
suspension prepared according to this invention are stable at least
for 12 months.
TABLE-US-00008 Azithromycin concentration (mg) Storage 1 2 3 6 12
Condition Initial Month Month Month Month Month 25.degree. 83.0
84.9 84.0 84.7 84.3 83.2 C./60% RH 40.degree. 83.0 79.7 85.0 82.0
80.9 Not C./75% measured RH
TABLE-US-00009 Azithromycin recovery over the Initial Conc. (%)
Storage 1 2 3 6 12 Condition Initial Month Month Month Month Month
25.degree. 100 102.3 101.2 102.0 101.5 100.2 C./60% RH 40.degree.
100 96.1 102.4 98.8 97.4 Not C./75% measured RH
TABLE-US-00010 pH of Azithromycin SR pellets Storage 1 2 3 6 12
Condition Initial Month Month Month Month Month 25.degree. 9.06
8.83 8.92 9.08 9.33 9.35 C./60% RH 40.degree. 9.06 8.84 9.09 9.16
8.94 Not C./75% measured RH
TABLE-US-00011 Moisture level of Azithromycin SR pellets (%)
Storage 1 2 3 6 12 Condition Initial Month Month Month Month Month
25.degree. 0.44 0.48 0.63 0.69 0.56 0.51 C./60% RH 40.degree. 0.44
0.76 0.62 0.68 0.52 Not C./75% measured RH
TABLE-US-00012 Appearance of Azithromycin SR pellets Storage 1 2 3
6 12 Condition Initial Month Month Month Month Month 25.degree.
White, Same Same Same Same Same C./60% non-aggre- RH gated,
non-sticky 40.degree. White, Same Same Same Same Not C./75%
non-aggre- measured RH gated, non-sticky
Example 10
Preparation of Valacyclovir Sustained Release Spherical Pellets
[0295] A dry blend of 100 g of valacyclovir, 50 g of hydrogenated
cottonseed oil, NF (STEROTEX.RTM., by Abitec Corp.), 28 g of
microcrystalline cellulose, NF (AVICEL.RTM. by FMC Biopolymers),
0.04 g BHA and 22 g of pregelatinized starch (STARCH 1500.RTM. by
Colorcon Corp.) is wet massed with a water-propylene glycol mixture
(60:40=v:v), extruded, spheronized, dried and heated according to
the method described in Example 1 to form dry spherical pellets.
Alternatively, the dry blend is wet massed, extruded, fragmented,
dried and heated according to the method described in Example 2 to
form dry non-spherical pellets. The pellets thus prepared can be
further mixed to a vehicle similar to the one described in Example
8 to obtain a powder blend for oral suspension. Such suspension may
be used for treatment or prophylaxis of viral infections by a
single-dose regimen, i.e., one dose (1 g or more valacyclovir) per
treatment.
Example 11
Preparation of Antacid Sustained Release Spherical Pellets
[0296] A dry blend of 853.3 g of aluminum hydroxide, USP, 426.7 g
magnesium hydroxide, 80 g of hydrogenated cottonseed oil, NF
(STEROTEX.RTM., by Abitec Corp.), 144 g of microcrystalline
cellulose, NF (AVICEL.RTM. by FMC Biopolymers), and 96 g of
pregelatinized starch (STARCH 1500.RTM. by Colorcon Corp) was wet
massed, extrudated, spheronized, dried and heated according to the
method described in Example 1 to form dry spherical pellets. The
thus prepared pellets were spherical in shape with a moisture
content of 2.6% w/w.
[0297] Another dry blend of 65 g of sodium phosphate tribasic, 20 g
of hydrogenated cottonseed oil, NF (STEROTEX.RTM. by Abitec Corp.),
9 g of microcrystalline cellulose, NF (AVICEL.RTM. by FMC
Biopolymers), and 6 g of pregelatinized starch (STARCH 1500.RTM. by
Colorcon Corp) was wet massed, extrudated, spheronized, dried and
heated according to the method described in Example 1 to form dry
spherical pellets. The thus prepared pellets were spherical in
shape.
[0298] The mixture of pellets was prepared by mixing well 9 weight
parts of dry spherical pellets containing aluminum hydroxide and
magnesium hydroxide and 1 weight part of dry spherical pellets
containing sodium phosphate tribase and was tested in horses for
antacid activities.
Example 12
Preparation of Vitamin-Mineral, Sustained Release Spherical
Pellets
[0299] A dry blend of 100 g of a vitamin (such as vitamin A, B, C,
D, and E), a mineral (such as calcium, iron and zinc), or a mixture
thereof, 50 g of hydrogenated cottonseed oil, NF (STEROTEX.RTM., by
Abitec Corp.), 28 g of microcrystalline cellulose, NF (AVICEL.RTM.
by FMC Biopolymers), 0.04 g BHA and 22 g of pregelatinized starch
(STARCH 1500.RTM. by Colorcon Corp.) is wet massed, extruded,
spheronized, dried and heated according to the method described in
Example 1 to form dry spherical pellets. Alternatively, the dry
blend is wet massed, extruded, fragmented, dried and heated
according to the method described in Example 2 to form dry
non-spherical pellets. The pellets thus prepared can be mixed to a
flavor such as molasses powder or a vehicle similar to the one
described in Example 8 to obtain a powder blend for oral
suspension. The said powder blend may be provided to animals such
as horses for voluntary consumption or to human patients as an oral
suspension. Such suspension may be used for a prolonged supply of
vitamins and minerals to a human or animal subject in need of such
supplement by a single-dose regimen, i.e., one dose (1 g or more of
a vitamin, mineral or mixture thereof) per day.
Example 13
Preparation of Ursodiol Sustained Release Spherical Pellets
[0300] A dry blend of 100 g of ursodiol, 50 g of hydrogenated
cottonseed oil, NF (STEROTEX.RTM., by Abitec Corp.), 28 g of
microcrystalline cellulose, NF (AVICEL.RTM. by FMC Biopolymers),
0.04 g BHA, and 22 g of pregelatinized starch (STARCH 1500.RTM. by
Colorcon Corp.) is wet massed, extruded, spheronized, dried and
heated according to the method described in Example 1 to form dry
spherical pellets. Alternatively, the dry blend is wet massed,
extruded, fragmented, dried and heated according to the method
described in Example 2 to form dry non-spherical pellets. The
pellets thus prepared can be mixed to a flavor such as molasses
powder or a vehicle similar to the one described in Example 8 to
obtain a powder blend for oral suspension. The said powder blend
may be provided to human patients as an oral suspension. Such
suspension is intended to dissolve gallstones in patients and for
treatment for primary biliary cirrhosis, and other cholestatic
diseases, including fat liver by a single-dose regimen, i.e., one
dose (1 g or more of ursodiol) per day.
Example 14
Preparation of Metformin Sustained Release Spherical Pellets
[0301] A dry blend of 100 g of metformin or its pharmaceutical
salt, alone or in combination with another antidiabetic drug
selected from sulfonylurea class (e.g., glyburide),
thiazolidinedione class (e.g., rosiglitazone, pioglitazone), or
DPP-4 inhibitors (e.g., Januvia), 50 g of hydrogenated cottonseed
oil, NF (STEROTEX.RTM., by Abitec Corp.), 28 g of microcrystalline
cellulose, NF (AVICEL.RTM. by FMC Biopolymers), 0.04 g BHA, and 22
g of pregelatinized starch (STARCH 1500.RTM. by Colorcon Corp.) is
wet massed, extruded, spheronized, dried and heated according to
the method described in Example 1 to form dry spherical pellets.
Alternatively, the dry blend is wet massed, extruded, fragmented,
dried and heated according to the method described in Example 2 to
form dry non-spherical pellets. The pellets thus prepared can be
mixed to a flavor such as molasses powder or a vehicle similar to
the one described in Example 8 to obtain a powder blend for oral
suspension. The powder blend may be provided to human patients as
an oral suspension. Such suspension may be used for treatment of
diabetes by a single-dose regimen, i.e., one dose (1 g or more of
active drug) per day.
Example 15
Preparation of Polyene Phosphatidylcholine Sustained Release
Spherical Pellets
[0302] A dry blend of 100 g of polyene phosphatidycholine, 50 g of
hydrogenated cottonseed oil, NF (STEROTEX.RTM., by Abitec Corp.),
28 g of microcrystalline cellulose, NF (AVICEL.RTM. by FMC
Biopolymers), 0.04 g BHA and 22 g of pregelatinized starch (STARCH
1500.RTM. by Colorcon Corp) is wet massed, extruded, spheronized,
dried and heated according to the method described in Example 1 to
form dry spherical pellets. Alternatively, the dry blend is wet
massed, extruded, fragmented, dried and heated according to the
method described in Example 2 to form dry non-spherical pellets.
The pellets thus prepared are capable of releasing the active
agent(s) in a sustained release fashion and can be mixed to a
flavor such as molasses powder or a vehicle similar to the one
described in Example 8 to obtain a powder blend for oral
suspension. The powder blend may be provided to human patients as
an oral suspension. Such suspension may be used for lowering
elevated hepatic enzyme levels, treatment of liver steatosis or
other hepatic disorder by a single-dose regimen, i.e., one dose (1
g or more of active drug) per day.
Example 16
Preparation of Gabapentin Sustained Release Spherical Pellets
[0303] A dry blend of 100 g of gabapentin, 50 g of hydrogenated
cottonseed oil, NF (STEROTEX.RTM., by Abitec Corp.), 28 g of
microcrystalline cellulose, NF (AVICEL.RTM. by FMC Biopolymers),
0.04 g BHA and 22 g of pregelatinized starch (STARCH 1500.RTM. by
Colorcon Corp.) is wet massed, extruded, spheronized, dried and
heated according to the method described in Example 1 to form dry
spherical pellets. Alternatively, the dry blend is wet massed,
extruded, fragmented, dried and heated according to the method
described in Example 2 to form dry non-spherical pellets. The
pellets can be mixed to a flavor such as molasses powder or a
vehicle similar to the one described in Example 8 to obtain a
powder bend for oral suspension. The powder blend may be provided
to human patients as an oral suspension. Such suspension is
intended for treatment of seizure or other neuropathic disorders by
a single-dose regimen, i.e., one dose (1 g or more of active drug)
per day.
Example 17
Comparison of In Vitro Dissolution of Glucosamine Pellets Processed
by Different Heating Conditions
[0304] An in vitro dissolution test was carried for the pellets
prepared according to this invention using a standard UPS
dissolution apparatus I (basket). The method is detailed as
follow:
TABLE-US-00013 APPARATUS: USP dissolution apparatus I (basket)
Medium: USP Simulated gastric fluid (without enzymes) Medium
volume: 500 mL Temperature: 37.degree. C. Stir: 50 PPM Sample
volume: 1 mL (without replenishment with fresh medium).
[0305] Each sample was filtered through a 10-micron filter prior to
filling into HPLC vial. Typical Sampling time: 0.5, 1, 2, 4, 8, 16
and 24 hours.
[0306] After 24 hours, the remaining pellet mass (soft gel-like)
was homogenized in the medium using a mechanical mixer to form a
uniform dispersion, which was then filtered through the 10-micron
filter and analyzed by HPLC as the "100% release" sample. The in
vitro release (%) values in all previous samples (0.5-24 hr) were
normalized based on the "100% release" using the following
equation: % release=100.times. (drug conc. in a previous
sample)(drug conc. in the "100% release sample").
[0307] The concentration of a drug in the medium samples was
analyzed using a HPLC method as described in detail below.
[0308] An ion-exchange HPLC method with the following conditions
was used for glucosamine analysis:
TABLE-US-00014 Column: Hamilton RCX-10 Mobile Phase: 10 mM NaOH in
water, 0.8 micron filtered Flow rate: 1.2 mL/min Column temp:
30.degree. C. Injection: 50 .mu.L UV Detection: 209 nm Run time: 7
min
[0309] A reverse phase HPLC method with the following conditions
was used for tramadol analysis:
TABLE-US-00015 System: An HPLC system capable of performing binary
gradient elution and UV detection Column: Luna C18 5.mu. 4.6
.times. 250 mm, by Phenomenex Mobile Phase A: 0.1% v/v
trifluoroacetic acid in water, 0.8 micron filtered Mobile Phase B:
0.1% v/v trifluoroacetic acid in acetonitrile, 0.8 micron filtered
Column temp: 40.degree. C. Flow rate: 1 mL/min Injection: 5 .mu.L
UV Detection: 270 nm Run time: 5 min Elution: Isocratic 65% (v/v)
Mobile Phase A and 35% (v/v) Mobile Phase B
[0310] The in vitro dissolution results from the glucosamine
spherical pellets are depicted in FIG. 7. It is apparent that the
drying/heating conditions had profound effects of the glucosamine
release. The pellets made with the 2 separate drying and heating
("pellets dried at 40.degree. C. and heated at 75.degree. C.")
exhibited the desired release profile, i.e., about 40% release in
the first hour and the rest in the next 23 hours in near zero-order
kinetic (linear). This 2-step dissolution profile is one of the
characteristics of the pellets prepared according to certain
embodiments of this invention, where the initial fast release of
about 40% of the drug load provides a quick onset of action (i.e.,
a loading dose) and the second phase of the extended release allows
for a prolonged action of the drug (i.e., a maintenance dose).
Pellets that were either dried/heated in one-step at a 40.degree.
C. for 30 minutes or 75.degree. C. for 30 minutes did not provide
the same extended release with about 85-90% drug released in about
12 hours. The results of this study indicate that the separate
drying at 40.degree. C. for 10 minutes and heating at 75.degree. C.
(above the melting point of the wax-like agent) for 15 minutes
render the sustained release property of the pellets.
Example 18
In Vitro Dissolution of Glucosamine from Pellets Prepared without a
Wax-Like Agent
[0311] Spherical pellets containing glucosamine with non-wax-like
oils (corn oil and soybean oil) or hydrogen-forming polymer
(hydroxypropy methylcellulose or HPMC) commonly used in sustained
release products were prepared using a method similar to what is
described in Example 1 and tested using the method for glucosamine
analysis according to Example 17. The results show that the non
wax-like agents (corn oil, soybean oil or HPMC) did not provide the
same sustained release property as a wax-like agent (hydrogenated
cottonseed oil). In fact, pellets made without the wax-like agent
released about or more than 80% of their drug load in the first
hour (FIG. 8).
Example 19
Preparation of Tramadol Hydrochloride Sustained Release Spherical
Pellets
[0312] A dry blend of 750 g of tramadol hydrochloride (Degussa),
750 g of hydrogenated cottonseed oil, NF (STEROTEX.RTM., by Abitec
Corp.) and 1000 g of microcrystalline cellulose, NF (AVICEL.RTM. by
FMC Biopolymers) was wet massed with about 900 gram water,
extrudated, spheronized, dried and heated according to the method
described in Example 1 to form dry spherical pellets. The thus
prepared pellets were spherical in shape with a moisture content of
0.42% w/w. The pellets were tested for in vitro dissolution and
exhibited a characteristic 2-phase dissolution profile with an
about 35% initial fast release followed by a 24 hour extended
release (FIG. 9). These pellets were tested in horses for
pharmacokinetic profiles.
Example 20
Pharmacokinetic Study of Tramadol Hydrochloride Sustained Release
Spherical Pellets
[0313] Six healthy adult horses, weighing approximately 600 kg,
were administered the tramadol sustained release spherical pellets
prepared according to Example 19 at a dosage of 10 mg/kg, orally,
as a top dress on feed. Twelve healthy adult horses, weighing
approximately 600 kg, were administered the tramadol active at a
dosage of 10 mg/kg, orally, as a top dress on feed. After the
single oral dose on Day 0, blood samples from all horses were
collected at various intervals after dosing and analyzed for
tramadol and the main active metabolite, M1.
[0314] Pharmacokinetic profiles of tramadol and M1 in horses
following oral administration of tramadol hydrochloride sustained
release spherical pellets (FIG. 10) and following oral
administration of unformulated tramadol hydrochloride (FIG. 11)
show that tramadol sustained release spherical pellets prepared as
described above appears to deliver tramadol at a relevant plasma
concentration over an extended period of time compared to
non-formulated drug.
Example 21
Antacid Activity Evaluation of Antacid Sustained Release Spherical
Pellets
[0315] The objective of this study was to evaluate the buffering
capacity of two antacid sustained release spherical pellet
formulations on gastric pH in horses. One formulation is the
spherical pellets that contain aluminum hydroxide and magnesium
hydroxide prepared according to Example 11. The other formulation
is a 9:1 combination of spherical pellets that contain aluminum
hydroxide and magnesium hydroxide and spherical pellets that
contain sodium phosphate tribase according to Example 11. Six
horses weighing approximately 500650 kg and with indwelling pH
electrodes were administered the antacid sustained release
spherical pellets orally, as a top dress on feed. Baseline gastric
pH measurements were compared to measurements at intervals post
dosing (FIG. 12). The results show that antacid agents formulated
in the sustained release spherical pellets according to Example 11
appear to affect the pH of the stomach for an extended period.
[0316] All of the above U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification and/or listed in the Application Data Sheet, are
incorporated herein by reference, in their entirety.
[0317] From the foregoing it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
* * * * *